

Wetenschappelijk overzicht IKNL 2023

Wetenschappelijk overzicht IKNL 2023

Auteur
A.M. Kuijpers-Ruurs

Inhoudsopgave

1	Algemeen	5
1.1	Publicaties met impactfactor	5
1.2	Overige publicaties	12
1.3	Proefschriften en promoties	13
2	Borstkanker	14
2.1	Publicaties met impactfactor	14
2.2	Overige publicaties	17
2.3	Proefschriften en promoties	18
3	Bot-en wekedelentumoren	19
3.1	Publicaties met impactfactor	19
4	Darmkanker	20
4.1	Publicaties met impactfactor	20
5	Gynaecologische tumoren	24
5.1	Publicaties met impactfactor	24
5.2	Overige publicaties	25
6	Hemato-oncologie	26
6.1	Publicaties met impactfactor	26
7	Hoofdhalskanker	29
7.1	Publicaties met impactfactor	29
8	Huidkanker	30
8.1	Publicaties met impactfactor	30
9	Longkanker	32
9.1	Publicaties met impactfactor	32
9.2	Overige publicaties	32
10	Neuro-oncologie	33
10.1	Publicaties met impactfactor	33
11	Upper GI & HPB	34
11.1	Publicaties met impactfactor	34
11.2	Proefschriften en promoties	37
12	Urogenitale kanker	38
12.1	Publicaties met impactfactor	38
12.2	Overige publicaties	41
12.3	Proefschriften en promoties	41
B1	Impactfactoren tijdschriften	42

1 Algemeen

1.1 Publicaties met impactfactor

Behroozian T, Goldshtein D, Ryan Wolf J, [van den Hurk CJ](#), Finkelstein S, Lam H, Patel P, Kanee L, Lee SF, Chan AW, Wong HCY, Caini S, Mahal S, Kennedy S, Chow E, Bonomo P; Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. [MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1\) systematic review](#). *EClinicalMedicine*. 2023 Mar 27;58:101886. doi: 10.1016/j.eclinm.2023.101886. eCollection 2023 Apr. Impactfactor: 15,1

Behroozian T, Bonomo P, Patel P, Kanee L, Finkelstein S, [van den Hurk CJ](#), Chow E, Wolf JR; Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. [Multinational Association of Supportive Care in Cancer \(MASCC\) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations](#). *Lancet Oncol*. 2023 Apr;24(4):e172-e185. doi: 10.1016/S1470-2045(23)00067-0. Impactfactor: 51,1

Behroozian T, Caini S, [van den Hurk CJ](#), Bonomo P, Chow E, Wolf JR. [Systematic review and meta-analysis on interventions for radiation dermatitis prevention and management: an overview of the methods](#). *Support Care Cancer*. 2023 Apr 13;31(5):261. doi: 10.1007/s00520-023-07707-5. Impactfactor: 3,1

Bergman T, [Lize N](#), [Beijer S](#), [Raijmakers NJ](#), Metselaar S. [A care ethics approach to a reduced ability to eat](#). *Nurs Ethics*. 2023 Sep 28;9697330231197708. doi: 10.1177/09697330231197708. Online ahead of print. Impactfactor: 4,2

Bongaerts THG, Büchner FL, [de Munck L](#), [Elferink MA](#), Guicherit OR, Numans ME. [Attendance characteristics of the breast and colorectal cancer screening programmes in a highly urbanised region of the Netherlands: a retrospective observational study](#). *BMJ Open*. 2023 Jun 23;13(6):e071354. doi: 10.1136/bmjopen-2022-071354. Impactfactor: 2,9

Buiting HM, Botman F, van der Velden LA, [Brom L](#), van Heest F, Bolt EE, de Mol P, Bakker T. [Clinicians' experiences with cancer patients living longer with incurable cancer: a focus group study in the Netherlands](#). *Prim Health Care Res Dev*. 2023 Apr 28;24:e29. doi: 10.1017/S1463423622000500. Impactfactor: 1,6

Chan DC, Wong HC, Riad MA, Caini S, Wolf JR, [van den Hurk CJ](#), Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. [Prevention of radiation dermatitis with skin hygiene and washing: a systematic review and meta-analysis](#). *Support Care Cancer*. 2023 Apr 22;31(5):294. doi: 10.1007/s00520-023-07720-8. Impactfactor: 3,1

[de Heus E](#), [van de Camp K](#), [Driehuis E](#), [van der Zwan JM](#), van Herpen CM, [Merkx MA](#), [Duijts SF](#). [The solitary versus supported experience: care inequality between rare and common cancer patients](#). *Psychooncology*. 2023 Sep 12. doi: 10.1002/pon.6216. Online ahead of print. Impactfactor: 3,6

Driessen HP, Busschbach JJ, van der Rijt CC, Elfrink EJ, [Raijmakers NJ](#), [van Roij J](#), Rietjens J, Kranenburg LW. [Unmet care needs of patients with advanced cancer and their relatives: multicentre observational study](#). *BMJ Support Palliat Care*. 2023 Jul 25;spcare-2023-004242. doi: 10.1136/spcare-2023-004242. Online ahead of print. Impactfactor: 2,7

Dijxhoorn AQ, Heijnen Y, van der Linden YM, Leget C, Raijmakers NJ, Brom L. Nursing assistants' perceptions and experiences with the emotional impact of providing palliative care: a qualitative interview study in nursing homes. *J Adv Nurs*. 2023 Jun 12. doi: 10.1111/jan.15733. Online ahead of print. Impactfactor:3,8

Ehrenstein JK, Duijts SF, van Zon SK, Amick III BC, Schagen SB, Bültmann U. Establishing General Working Population Norms for the Cognitive Symptom Checklist-Work. *J Occup Rehabil*. 2023 Mar 20. doi: 10.1007/s10926-023-10104-8. Online ahead of print. Impactfactor: 3,3

Fatima S, Hirakawa S, Marta GN, Caini S, Beveridge M, Bonomo P, Chow E, van den Hurk CJ, Ryan Wolf J, Lam H, Behroozian T. Topical non-steroidal agents for the prevention of radiation dermatitis: a systematic review and meta-analysis. *Support Care Cancer*. 2023 Mar 17;31(4):217. doi: 10.1007/s00520-023-07677-8. Impactfactor: 3,1

Gavai A, Bouzembrak Y, Mu W, Martin F, Kaliyaperumal R, van Soest J, Choudhury A, Heringa J, Dekker A, Marvin HJ. Author Correction: Applying federated learning to combat food fraud in food supply chains. *NPJ Sci Food*. 2023 Oct 19;7(1):57. doi: 10.1038/s41538-023-00232-z. Impactfactor: 6,4

Gavai A, Bouzembrak Y, Mu W, Martin F, Kaliyaperumal R, van Soest J, Choudhury A, Heringa J, Dekker A, Marvin HJ. Applying federated learning to combat food fraud in food supply chains. *NPJ Sci Food*. 2023 Sep 1;7(1):46. doi: 10.1038/s41538-023-00220-3. Impactfactor: 6,4

Gini A, Colombet M, de Paula Silva N, Visser O, Youlden D, Soerjomataram I, Stiller CA, Steliarova-Foucher E; CRICCS Consortium. A new method of estimating prevalence of childhood cancer survivors (POCCS): example of the 20-year prevalence in The Netherlands. *Int J Epidemiol*. 2023 Sep 20;dyad124. doi: 10.1093/ije/dyad124. Online ahead of print. Impactfactor: 7,7

Giusti F, Martos C, Trama A, Bettio M, Sanvisens A, Audisio R, Arndt V, Francisci S, Dochez C, Ribes J, Fernández LP, Gavin A, Gatta G, Marcos-Gragera R, Lievens Y, Allemani C, De Angelis R, Visser O, van Eycken L; ENCR Working Group on Treatment Data Harmonisation. Cancer treatment data available in European cancer registries: Where are we and where are we going? *Front Oncol*. 2023 Feb 8;13:1109978. doi: 10.3389/fonc.2023.1109978. eCollection 2023. Impactfactor: 4,7

Giusti F, Martos C, Negrão Carvalho R, van Eycken L, Visser O, Bettio M. Quality indicators: completeness, validity and timeliness of cancer registry data contributing to the European Cancer Information System. *Front Oncol*. 2023 Jul 28;13:1219128. doi: 10.3389/fonc.2023.1219128. eCollection 2023. Impactfactor: 4,7

Gobbo M, Rico V, Marta GN, Caini S, Ryan Wolf J, van den Hurk CJ, Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. Photobiomodulation therapy for the prevention of acute radiation dermatitis: a systematic review and meta-analysis. *Support Care Cancer*. 2023 Mar 23;31(4):227. doi: 10.1007/s00520-023-07673-y. Impactfactor: 3,1

Goedegebuur J, Abbel D, Accassat S, Achterberg WP, Akbari A, Arfuch VM, Baddeley E, Bax JJ, Becker D, Bergmeijer B, Bertolotti L, Blom JW, Calvetti A, Cannegieter SC, Castro L, Chavannes NH, Coma-Auli N, Couffignal C, Edwards A, Edwards M, Enggaard H, Font C, Gava A, Geersing GJ, Geijteman EC, Greenley S, Gregory C, Gussekloo J, Hoffmann I, Højten AA, van den Hout WB, Huisman MV, Jacobsen S, Jagosh J, Johnson MJ, Jørgensen L, Juffermans CC, Kempers EK, Konstantinides S, Kroder AF, Kruip MJ, Lafaie L, Langendoen JW, Larsen TB, Lifford K, van der Linden YM, Mahé I, Maiorana L, Maraveyas A, Martens ES, Mayeur D, van Mens TE, Mohr K, Mooijaart SP, Murtagh FE, Nelson A, Nielsen PB, Ording AG, Ørskov M, Pearson M, Poenou G, Portielje JE, Raczkiwicz D, Rasmussen K, Trinks-Roerdink E, Schippers I, Seddon K, Sexton K, Sivell S, Skjøth F, Søgaard M, Szmit S, Trompet S, Vassal P, Visser C, van Vliet LM, Wilson E, Klok FA, Noble SI. Towards optimal use of antithrombotic therapy of people with

cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool. *Thromb Res.* 2023 May 13;228:54-60. doi: 10.1016/j.thromres.2023.05.008. Online ahead of print. PMID: 37276718. Impactfactor: 7,5

Ham L, Slotman E, Burghout C, Raijmakers NJ, van de Poll-Franse LV, van Zuylen L, Fransen HP. Potentially inappropriate end-of-life care and its association with relatives' well-being: a systematic review. *Support Care Cancer.* 2023 Nov 30;31(12):731. doi: 10.1007/s00520-023-08198-0. Impactfactor: 3,1

Ham L, Fransen HP, Raijmakers NJ, van den Beuken-van Everdingen MH, van den Borne B, Creemers GJ, de Graeff A, Hendriks MP, de Jong WK, van Laarhoven H, van Leeuwen L, van der Padt-Pruijsten A, Smilde TJ, Stellingwerf M, van Zuylen L, van de Poll-Franse LV. Trajectories of emotional functioning and experienced care of relatives in the last year of life of patients with advanced cancer: a longitudinal analysis of the eQuiPe study. *Psychooncology.* 2023 Oct 26. doi: 10.1002/pon.6233. Online ahead of print. Impactfactor: 3,6

Heibloem RE, Komen MM, Ilozumba OU, **van den Hurk CJ.** Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry. *Support Care Cancer.* 2023 Apr 17;31(5):273. doi: 10.1007/s00520-023-07687-6. Impactfactor: 3,1

Helsper CW, Van Gils CH, Van Erp NF, Siepman van den Berg MF, Rogouti O, van Asselt KM, Maarsingh OR, Muris J, Brandenburg D, **Siesling S, De Wit NJ, Grant MP,** on Behalf Of The Covid And Cancer Consortium. Impact of the COVID-19 outbreak-delayed referral of colorectal and lung cancer in primary care: a national retrospective cohort study. *Cancers (Basel).* 2023 Feb 25;15(5):1462. doi: 10.3390/cancers15051462. Impactfactor: 5,2

Hermans KE, Kazemzadeh F, **Loef C, Jansen RL, Nagtegaal ID, van den Brandt PA, Schouten LJ.** Risk factors for cancer of unknown primary: a literature review. *BMC Cancer.* 2023 Apr 5;23(1):314. doi: 10.1186/s12885-023-10794-6. Impactfactor: 3,8

Hiensch AE, Beckhaus J, Witlox L, Monninkhof EM, Schagen SB, van Vulpen JK, Sweegers MG, Newton RU, Aaronson NK, Galvão DA, Steindorf K, Stuiver MM, Mesters I, Knoop H, Goedendorp MM, Bohus M, Thorsen L, Schulz KH, Schmidt ME, Ulrich CM, Sonke GS, van Harten WH, Winters-Stone KM, **Velthuis MJ, Taaffe DR, van Mechelen W, Kersten MJ, Nollet F, Wiskemann J, Buffart LM, May AM.** Moderators of exercise effects on self-reported cognitive functioning in cancer survivors: an individual participant data meta-analysis. *J Cancer Surviv.* 2023 May 9. doi: 10.1007/s11764-023-01392-3. Online ahead of print. Impactfactor: 3,7

Hinnen C, Hochstenbach S, **Mols F, Mertens BJ.** Comparing survival rates for clusters of depressive symptoms found by Network analysis' community detection algorithms: results from a prospective population-based study among 9774 cancer survivors from the PROFILES-registry. *Br J Clin Psychol.* 2023 Aug 22. doi: 10.1111/bjc.12435. Online ahead of print. Impactfactor: 3,1

Hollestein LM, Ye MY, Ang KL, Forbes H, Mansfield KE, Abuabara K, Smeeth L, Langan SM. The association between atopic eczema and lymphopenia: results from a UK cohort study with replication in US survey data. *J Eur Acad Dermatol Venereol.* 2023 Jan 6. doi: 10.1111/jdv.18841. Online ahead of print. Impactfactor: 9,2

Janssen SH, **Vlooswijk C, Manten-Horst E, Sleeman SH, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Lalisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O.** Learning from long-term adolescent and young adult (AYA) cancer survivors regarding their age-specific care needs to improve current AYA care programs. *Cancer Med.* 2023 Apr 29. doi: 10.1002/cam4.6001. Online ahead of print. Impactfactor: 4,0

Larønningen S, Skog A, Engholm G, Ferlay J, Johannesen TB, Kristiansen MF, **Knoors D**, König SM, Olafsdottir EJ, Pejčic S, Pettersson D, Skovlund CW, Storm HH, Tian H, Aagnes B, Miettinen J. Nordcan.R: a new tool for federated analysis and quality assurance of cancer registry data. *Front Oncol*. 2023 Aug 8;13:1098342. doi: 10.3389/fonc.2023.1098342. eCollection 2023. Impactfactor: 4,7

Levinsen AK, **van de Poll-Franse VL**, **Ezendam N**, **Aarts MJ**, Kjaer TK, Dalton SO, **Oerlemans S**. Socioeconomic differences in health-related quality of life among cancer survivors and comparison with a cancer-free population: a PROFILES study. *J Cancer Surviv*. 2023 Nov 29. doi: 10.1007/s11764-023-01494-y. Online ahead of print. Impactfactor: 3,7

Liu M, Christ L, **Richters A**, Özdemir BC. Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease. *Oncol Lett*. 2023 Jul 18;26(3):377. doi: 10.3892/ol.2023.13963. eCollection 2023 Sep. Impactfactor: 2,9

Luyendijk M, **Visser O**, Blommestein HM, de Hingh IH, Hoebbers FJ, Jager A, Sonke GS, de Vries EG, Uyl-de Groot CA, **Siesling S**. Changes in survival in de novo metastatic cancer in an era of new medicines. *J Natl Cancer Inst*. 2023 Mar 29:djad020. doi: 10.1093/jnci/djad020. Online ahead of print. Impactfactor: 10,3

Maas CC, van Klaveren D, **Visser O**, **Merkx MA**, Lingsma HF, **Lemmens VE**, **Dinmohamed AG**. Number of life-years lost at the time of diagnosis and several years post-diagnosis in patients with solid malignancies: a population-based study in the Netherlands, 1989-2019. *EClinicalMedicine*. 2023 May 11;60:101994. doi: 10.1016/j.eclinm.2023.101994. eCollection 2023 Jun. Impactfactor: 15,1

Malhotra A, **Fransen HP**, Quaresma M, **Raijmakers N**, **Versluis MA**, Rachet B, **van Maaren MC**, Leyrat C. Associations between treatments, comorbidities and multidimensional aspects of quality of life among patients with advanced cancer in the Netherlands—a 2017-2020 multicentre cross-sectional study. *Qual Life Res*. 2023 Jun 30. doi: 10.1007/s11136-023-03460-8. Online ahead of print. Impactfactor: 3,5

Mitchell H, Mclean J, Gavin AT, **Visser O**, Millar E, Luff T, Bennett D. Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses: a comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland. *BMC Cancer*. 2023 Jul 26;23(1):700. doi: 10.1186/s12885-023-11216-3. Impactfactor: 3,8

Oosting SF, van der Veldt AA, Fehrmann RS, Bhattacharya A, van Binnendijk RS, GeurtsvanKessel CH, Dingemans AC, Smit EF, Hiltermann TJ, den Hartog G, Jalving M, **Westphal TT**, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CA, Rots NY, van Baarle D, Haanen JB, de Vries EG. Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors. *ESMO Open*. 2023 Jun 21;8(4):101599. doi: 10.1016/j.esmoop.2023.101599. Online ahead of print. Impactfactor: 7,3

Özdemir BC, **Richters A**, Espinosa da Silva C, Berner AM. Cancer researchers' perceptions of the importance of the sex of cell lines, animals, and human samples for cancer biology research. *iScience*. 2023 Feb 16;26(4):106212. doi: 10.1016/j.isci.2023.106212. eCollection 2023 Apr 21. Impactfactor: 5,8

Paschos S, **Lize N**, Eussen S, van der Padt-Pruijsten A, van den Beuken-van Everdingen M, van Laarhoven H, den Boer M, de Graeff A, van den Borne B, Ten Have H, Kennis M, **Beijer S**, **Raijmakers NJ**, **van de Poll-Franse LV**. Are gastrointestinal problems, nutritional care, and nutritional care needs associated with quality of life in patients with advanced cancer? Results of the observational eQuiPe study. *Support Care Cancer*. 2023 Feb 27;31(3):189. doi: 10.1007/s00520-023-07646-1. PMID: 36847908. Impactfactor: 3,1

Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, **Koopman M**, Delalogue S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi AL. *Artificial Intelligence for predictive biomarker discovery in immuno-oncology: a systematic review*. *Ann Oncol*. 2023 Oct 23:S0923-7534(23)04331-4. doi: 10.1016/j.annonc.2023.10.125. Online ahead of print. Impactfactor: 50,5

Robijns J, Aquilano M, Banerjee S, Caini S, Wolf JR, **van den Hurk CJ**, Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. *Barrier Films and Dressings for the Prevention of Acute Radiation Dermatitis: A Systematic Review and Meta-Analysis*. *Support Care Cancer*. 2023 Mar 17;31(4):219. doi: 10.1007/s00520-023-07671-0. Impactfactor: 3,1

Robijns J, Aquilano M, Banerjee S, Caini S, Wolf JR, **van den Hurk CJ**, Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. *Correction to: Barrier films and dressings for the prevention of acute Radiation dermatitis: a systematic review and meta-analysis*. *Support Care Cancer*. 2023 May 12;31(6):333. doi: 10.1007/s00520-023-07807-2. Impactfactor: 3,1

Robijns J, Becherini C, Caini S, Wolf JR, **van den Hurk CJ**, Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. *Natural and miscellaneous agents for the prevention of acute radiation dermatitis: a systematic review and meta-analysis*. *Support Care Cancer*. 2023 Mar 2;31(3):195. doi: 10.1007/s00520-023-07656-z. Impactfactor: 3,1

Scholte M, Heidkamp J, Hannink G, **Merkx MA**, Grutters JP, Rovers MM. *Care pathway analysis to inform the earliest stages of technology development: scoping oncological indications in need of innovation*. *Value Health*. 2023 Sep 25:S1098-3015(23)03132-7. doi: 10.1016/j.jval.2023.08.014. Online ahead of print. Impactfactor: 4,5

Schuurman MS, Lemmens VE, Portielje JE, **van der Aa MA, Visser O, Dinmohamed AG**. *The cancer burden in the oldest-old: Increasing numbers and disparities: a nationwide study in the Netherlands, 1990 to 2019*. *Int J Cancer*. 2023 Sep 4. doi: 10.1002/ijc.34705. Online ahead of print. Impactfactor: 6,4

Siebinga TM, Janssen SH, Boumans AW, **van Eenbergen MC**, Siflinger B, van der Graaf WT, Husson O. *Financial outcomes of Adolescent and Young Adult cancer survivors: a longitudinal population-based registry study*. *J Natl Cancer Inst*. 2023 Jun 6:djad107. doi: 10.1093/jnci/djad107. Online ahead of print. Impactfactor: 10,3

Slotman E, Franssen HP, van Laarhoven HW, van den Beuken-van Everdingen MH, Tjan-Heijnen VC, Huijben AM, Jager A, van Zuylen L, Kuip EJ, van der Linden YM, **Raijmakers NJ, Siesling S**. *Reduction in potentially inappropriate end-of-life hospital care for cancer patients during the COVID-19 pandemic: a retrospective population-based study*. *Palliat Med*. 2023 Dec 23:2692163231217373. doi: 10.1177/02692163231217373. Online ahead of print. Impactfactor: 4,4

Snijders RA, Brom L, Simons SO, Langenberg SM, **van der Linden YM, Raijmakers NJ**. *Referrals to palliative care services for hospitalised COVID-19 patients: a systematic literature review*. *Am J Hosp Palliat Care*. 2023 Nov 17:10499091231215797. doi: 10.1177/10499091231215797. Online ahead of print. Impactfactor: 1,9

Snijders RA, Brom L, Theunissen M, van den Beuken-van Everdingen MH. *Update on Prevalence of Pain in Patients with Cancer 2022: a Systematic Literature Review and Meta-Analysis*. *Cancers (Basel)*. 2023 Jan 18;15(3):591. doi: 10.3390/cancers15030591. Impactfactor: 5,2

Tam S, Zhou G, Trombetta M, Caini S, Ryan Wolf J, **van den Hurk CJ**, Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. *Topical corticosteroids for the prevention of severe radiation dermatitis: a*

systematic review and meta-analysis. *Support Care Cancer*. 2023 Jun 6;31(7):382. doi: 10.1007/s00520-023-07820-5.

Impactfactor: 3,1

van de Graaf DL, Moles F, Smeets T, Trompetter HR, van der Lee ML. Coping with and self-management of chronic painful chemotherapy-induced peripheral neuropathy: a qualitative study among cancer survivors. *J Cancer Surviv*. 2023 Sep 23. doi: 10.1007/s11764-023-01466-2. Online ahead of print.

Impactfactor: 3,7

van de Graaf DL, Engelen V, de Boer A, Vreugdenhil G, Smeets T, van der Lee ML, Trompetter HR, Moles F. Experiences of cancer survivors with chemotherapy-induced peripheral neuropathy in the Netherlands: symptoms, daily limitations, involvement of healthcare professionals, and social support. *J Cancer Surviv*. 2023 May 24. doi: 10.1007/s11764-023-01402-4. Online ahead of print.

Impactfactor: 3,7

van de Graaf DL, Smeets T, van der Lee ML, Trompetter HR, Baars-Seebregts A, Børøund E, Solberg Nes L, Schreurs KM, Moles F. Patient-centered development of *Embrace Pain*: an online acceptance and commitment therapy intervention for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy. *Acta Oncol*. 2023 Mar 20:1-13. doi: 10.1080/0284186X.2023.2187260. Online ahead of print.

Impactfactor: 3,1

van den Berg VE, Thölking TW, Leget CJ, **Hartog ID, Zomers ML, van Delden JJ, van Wijngaarden EJ.** Questioning the value of present life: The lived experience of older people who see no future for themselves. *Aging Ment Health*. 2023 Apr 10:1-9. doi: 10.1080/13607863.2023.2197850. Online ahead of print.

Impactfactor: 3,4

van der Meer DJ, Zevenbergen S, **Vlooswijk C, Bijlsma RM, Kaal SE, Kerst JM, Tromp JM, Bos ME, van der Hulle T, Laisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O.** Patient-Reported Outcomes of accelerated aging: a novel approach to investigate second cancer risk in adolescent and young adult (18-39 Years) cancer survivors. *Oncologist*. 2023 Nov 23:oyad307. doi: 10.1093/oncolo/oyad307. Online ahead of print.

Impactfactor: 5,8

van der Meulen AI, Neis EP, de Nijs EJ, Coenegracht BJ, **Stoppelenburg A, van den Beuken-van Everdingen MH, van der Linden YM.** Dry mouth in patients with a life-limiting condition or frailty: a study protocol for two intervention studies and a nested qualitative sub-study (the Dry mOuth Project, DROP). *BMC Palliat Care*. 2023 Aug 23;22(1):120. doi: 10.1186/s12904-023-01242-0.

Impactfactor: 3,1

van der Steen JT, Engels Y, Touwen DP, Kars MC, Reyners AK, **van der Linden YM, Korfae IJ.** Advance care planning in the Netherlands. *Z Evid Fortbild Qual Gesundheitswes*. 2023 Jul 21:S1865-9217(23)00136-8. doi: 10.1016/j.zefq.2023.06.003.

Impactfactor: 1,1

van der Veldt AA, Oosting SF, Fehrmann RS, GeurtsvanKessel CH, van Binnendijk RS, Dingemans AC, Smit EF, Hiltermann TJ, Hartog GD, Jalving M, **Westphal TT, Bhattacharya A, de Wilt F, Ernst SM, Boerma A, van Zijl L, Rimmelzwaan GF, Kvistborg P, van Els CA, Rots NY, van Baarle D, Haanen JB, de Vries EG.** One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment. *ESMO Open*. 2023 Jan 10;8(1):100785. doi: 10.1016/j.esmoop.2023.100785. Online ahead of print.

Impactfactor: 7,3

van Ommen F, Coenen P, Malekzadeh A, de Boer AG, Greidanus MA, **Duijts SF.** Interventions for work participation of unemployed or work-disabled cancer survivors: a systematic review. *Acta Oncol*. 2023 Apr 3:1-12. doi: 10.1080/0284186X.2023.2187261. Online ahead of print.

Impactfactor: 3,1

van Oss A, Duijts SF, van Laarhoven H, Kuip E, Raijmakers NJ, Brom L. Quality of care and quality of life as experienced by patients with advanced cancer of a rare tumour type: results of the multicentre

observational eQuiPe study. *J Cancer Surviv.* 2023 Jan 3. doi: 10.1007/s11764-022-01323-8. Online ahead of print.

Impactfactor: 3,7

van Teunenbroek KC, Kremer LC, Verhagen AA, Verheijden JM, Rippen H, **Borggreve BC**, Michiels EM, Mulder RL; Dutch Paediatric Palliative Care Guideline Panel. *Palliative care for children: methodology for the development of a national clinical practice guideline.* *BMC Palliat Care.* 2023 Dec 1;22(1):193. doi: 10.1186/s12904-023-01293-3.

Impactfactor: 3,1

van Tuijl LA, Basten M, Pan KY, Vermeulen R, Portengen L, de Graeff A, Dekker J, Geerlings MI, Hoogendoorn A, Lamers F, **Voogd AC**, Abell J, Awadalla P, Beekman AT, Bjerkeset O, Boyd A, Cui Y, Frank P, Galenkamp H, Garssen B, Hellingman S, Huisman M, Huss A, de Jong TR, Keats MR, Kok AA, Krokstad S, van Leeuwen FE, Luik AI, Noisel N, Onland-Moret NC, Payette Y, Penninx BW, Rissanen I, Roest AM, Ruitter R, Schoevers RA, Soave D, Spaan M, Steptoe A, Stronks K, Sund ER, Sweeney E, Twait EL, Teyhan A, Verschuren WM, van der Willik KD, Rosmalen JG, Ranchor AV. *Depression, anxiety, and the risk of cancer: an individual participant data meta-analysis.* *Cancer.* 2023 Aug 7. doi: 10.1002/cncr.34853. Online ahead of print.

Impactfactor: 6,2

van Vliet ED, **Eijkelboom AH**, van Giessen A, **Siesling S**, de Wit GA. *Physical and mental health outcomes of COVID-19 induced delay in oncological care: a systematic review.* *Front Oncol.* 2023 Jan 27;13:998940. doi: 10.3389/fonc.2023.998940. eCollection 2023.

Impactfactor: 4,7

Versluis MA, Raijmakers NJ, Baars A, van den Beuken-van Everdingen MH, de Graeff A, Hendriks MP, de Jong WK, Kloover JS, Kuip EJ, Mandigers CM, Sommeijer DW, **van der Linden YM, van de Poll-Franse LV**. *Trajectories of health-related quality of life and symptom burden in patients with advanced cancer towards the end of life: longitudinal results from the eQuiPe study.* *Cancer.* 2023 Oct 13. doi: 10.1002/cncr.35060. Online ahead of print.

Impactfactor: 6,2

Visser O, Kościńska B, Caetano Dos Santos FL, Cuccaro F, Forjaz G, Michalek IM, Mousavi M, Sulkowska U, Martos C, Giusti F. *2022 revised European recommendations for the coding of the basis of diagnosis of cancer cases in population-based cancer registries.* *Front Oncol.* 2023 Dec 12;13:1250549. doi: 10.3389/fonc.2023.1250549. eCollection 2023.

Impactfactor: 4,7

Vlooswijk C, Janssen SH, **van de Poll-Franse LV**, Bijlsma R, Kaal SE, Kerst JM, Tromp JM, Bos ME, Lalisang RI, Nuver J, Kouwenhoven MC, van der Graaf WT, Husson O. *Health-related quality of life of Adolescent and Young Adult Cancer Survivors before and during the COVID-19 pandemic: longitudinal improvements on social functioning and fatigue.* *J Patient Rep Outcomes.* 2023 Sep 13;7(1):93. doi: 10.1186/s41687-023-00629-0.

Impactfactor: 2,7

Vrinzen CE, Delfgou L, Stadhouders N, Hermens RP, **Merks MA**, Bloemendal HJ, Jeurissen PP. *A systematic review and multilevel regression analysis reveals the comorbidity prevalence in cancer.* *Cancer Res.* 2023 Apr 4;83(7):1147-1157. doi: 10.1158/0008-5472.CAN-22-1336.

Impactfactor: 11,2

Vrinzen CE, Bloemendal HJ, Stuart E, Makady A, van Agthoven M, Koster M, **Merks MA**, Hermens RP, Jeurissen PP. *Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?* *Cancer Med.* 2023 Mar;12(5):6105-6116. doi: 10.1002/cam4.5336.

Impactfactor: 4,0

Walraven JE, Verhoeven RH, Meulen RV, Hoeven JJ, **Lemmens VE**, Hesselink G, Desar IM. *Facilitators and barriers to conducting an efficient, competent and high-quality oncological multidisciplinary team meeting.* *BMJ Open Qual.* 2023 Feb;12(1):e002130. doi: 10.1136/bmjopen-2022-002130.

Impactfactor: 1,4

Walraven JE, Verhoeven RH, van der Hoeven JJ, van der Meulen R, Lemmens VE, Hesselink G, Desar IM. Pros and cons of streamlining and use of computerised clinical decision support systems to future-proof oncological multidisciplinary team meetings. *Front Oncol*. 2023 May 18;13:1178165. doi: 10.3389/fonc.2023.1178165. eCollection 2023. Impactfactor: 4,7

Weemaes AT, Meijer R, Beelen M, van Hooff M, Weijenberg MP, Lenssen AF, van de Poll-Franse LV, Savelberg HHCM, Schep G. Monitoring aerobic capacity in cancer survivors using self-reported questionnaires: criterion validity and responsiveness. *J Patient Rep Outcomes*. 2023 Jul 19;7(1):73. doi: 10.1186/s41687-023-00613-8. Impactfactor: 2,7

Wind A, Oberst S, Westerhuis W, Blaauwgeers H, Sæter G, de Paoli P, Nagy P, Burrion JB, Jolly E, Lovey J, van Harten W. Evaluating comprehensive cancer networks; a review of standards and evaluation methods for care networks to inform a comparison with the OECl comprehensive cancer network standards. *Acta Oncol*. 2023 Feb 14:1-10. doi: 10.1080/0284186X.2023.2170275. Online ahead of print. Impactfactor: 3,1

Wolters R, Mokadem I, Wensing M, Braspenning J. Supporting care engagement in primary care; the development of a maturity matrix. *PLoS One*. 2023 Jan 5;18(1):e0279542. doi: 10.1371/journal.pone.0279542. eCollection 2023. Impactfactor: 3,7

Zijlstra M, van Roij J, Henselmans I, van Laarhoven HW, Creemers GJ, Vreugdenhil G, Kuip EJ, van de Poll-Franse LV, Raijmakers NJ; eQuiPe study group. Perception of prognosis and health-related quality of life in patients with advanced cancer: results of a multicentre observational study (eQuiPe). *Support Care Cancer*. 2023 Feb 13;31(3):165. doi: 10.1007/s00520-023-07631-8. Impactfactor: 3,1

1.2 Overige publicaties

Arndt V, Siesling S. Krebsregistrierung in Europa. *Die Onkologie* 2023 Dec (18).

Atema V, de Korte A, de Ligt KM, Bouman V, Lunter S, Vos T, Horevoorts N, Lammens C, de Rooij BH. Behandeling van een aanpassingsstoornis na kanker: resultaten van een landelijke studie. *Ned Tijdschr Geneesk*. 2023;167:D7021.

de Boer EC, Versluis MA, Vissers PJ, Slingerland M, Haberkorn BC, de Ruitter MB, Dingemans IH, van de Poll-Franse LV, Reyners AK, Machteld Wymenga AN. Hoe lang zijn patiënten bereid te reizen voor medisch-oncologische zorg?: de reisbereidheid. *Ned Tijdschr Geneesk* 2023;167D7989.

de Vries S, Verhoef MJ, Vervoort SC, van der Linden YM, Teunissen SC, de Graaf E. Barriers and facilitators that hospital clinicians perceive to discuss the personal values, wishes, and needs of patients in palliative care: a mixed-methods systematic review. *Palliat Care Soc Pract*. 2023 Dec 1;17:26323524231212510. doi: 10.1177/26323524231212510. eCollection 2023.

Puts GC, Wauben-Spaetgens BM, Luth TT, Kruijt AW, Albada A, Praagman J, Visser O. Ontwikkeling van de kans op kanker in 1990-2019. *Ned Tijdschr Geneesk*. 2023;167:D7498.

Salako O, Enyi A, Miesfeldt S, Kabukye JK, Ngoma M, Namisango E, LeBaron V, Sisimayi C, Ebenso B, Lorenz KA, Wang Y, Ryan Wolf J, van den Hurk CJ, Allsop M. Remote symptom monitoring to enhance the delivery of palliative cancer care in low-resource settings: emerging approaches from Africa. *Int J Environ Res Public Health*. 2023 Dec 17;20(24):7190. doi: 10.3390/ijerph20247190.

van den Hurk CJ, Libreros-Peña L, Winstanley J, Arif A, Schaffrin-Nabe D, de Vries E, Young A, Boyle F. The HAIR-Qol measure part 1: what are the quality of life issues for people with cancer with chemotherapy-induced alopecia? *Measurement and Evaluations in Cancer Care* 1 (2023) 100002.

Winstanley J, Libreros-Peña L, Schaffrin-Nabe D, Arif A, de Vries E, Young A, Markussen A, Rugo HS, Dercksen M, Kinoshita T, Boyle F. van den Hurk CJ, The HAIR-Qol measure part 2: validation of an

instrument to measure of the severity and impact of chemotherapy-induced alopecia (CIA). Measurement and Evaluations in Cancer Care 1 (2023) 100003.

1.3 Proefschriften en promoties

Boddaert M. Quality palliative care for all: want it: towards death, while alive. Leiden: Tilburg University; 15 maart 2023. Promotor: **LV van der Poll Franse**. Copromotores: **S Beijer, NJ Raijmakers**.

Lize N. Food is more than nutrition: psychosocial consequences of a reduced ability to eat in patients with cancer. Tilburg: Tilburg University; 3 juli 2023. Promotor: **LV van der Poll Franse**. Copromotores: **S Beijer, NJ Raijmakers**.

2 Borstkanker

2.1 Publicaties met impactfactor

Beenhakker L, Wijlens KA, Witteveen A, Heins M, Korevaar JC, de Ligt KM, Bode C, Vollenbroek-Hutten MM, **Siesling S**. Development of machine learning models to predict cancer-related fatigue in Dutch breast cancer survivors up to 15 years after diagnosis. *J Cancer Surviv*. 2023 Dec 7. doi: 10.1007/s11764-023-01491-1. Online ahead of print.
Impactfactor: 3,7

Dassen RR, Pelders S, **de Munck L**, Jager A, Hooning MJ, van Dam JH, Heemskerk-Gerritsen BA. The effect of attendance in the Dutch breast cancer screening program on breast tumor characteristics among migrant women. *Breast*. 2023 Mar 15;69:290-298. doi: 10.1016/j.breast.2023.03.008. Online ahead of print.
Impactfactor: 3,9

de Ligt KM, **de Rooij BH**, Hedayati E, Karsten MM, Smaardijk VR, Velting M, Saunders C, Travado L, Cardoso F, Lopez E, Carney N, Wengström Y, Ives A, Velikova G, Sousa Fialho MDL, Seidler Y, Stamm TA, Koppert LB, **van de Poll-Franse LV**; Innovative Medicines Initiative - Health Outcomes Observatory (H2O) consortium. International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients. *Breast Cancer Res Treat*. 2023 Jan 20. doi: 10.1007/s10549-022-06827-6. Online ahead of print.
Impactfactor: 3,8

de Ligt KM, **de Rooij BH**, Koppert LB, **van de Poll-Franse LV**, Velikova G, Cardoso F. Patient-reported outcome measures to improve the care continuum for patients with metastatic breast cancer: opportunities and implications for nursing practice. *Semin Oncol Nurs*. 2023 Oct 11:151510. doi: 10.1016/j.soncn.2023.151510. Online ahead of print.
Impactfactor: 2,2

de Maar JS, Luyendijk M, Suelmann BB, van der Kruijssen DE, Elias SG, **Siesling S**, van der Wall E. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference: a Dutch population-based study from 2008 to 2018. *Breast Cancer Res Treat*. 2023 Apr;198(2):253-264. doi: 10.1007/s10549-022-06837-4. Epub 2023 Jan 17.
Impactfactor: 3,8

de Munck L, **Eijkelboom AH**, Otten JD, Broeders MJ, **Siesling S**. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. *J Natl Cancer Inst*. 2023 Nov 3:djad230. doi: 10.1093/jnci/djad230. Online ahead of print.
Impactfactor: 10,3

de Wild SR, Koppert LB, **de Munck L**, Vrancken Peeters MT, **Siesling S**, Smidt ML, Simons JM. Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study. *Breast Cancer Res Treat*. 2023 Dec 22. doi: 10.1007/s10549-023-07178-6. Online ahead of print.
Impactfactor: 3,8

Eijkelboom AH, **de Munck L**, Larsen M, **Bijlsma MJ**, Tjan-Heijnen VC, van Gils CH, Broeders MJ, Nygård JF, Lobbes MB, Helsper CW, Pijnappel RM, Strobbe LJ, Wesseling J, Hofvind S, **Siesling S**; NABON-COVID-19 Consortium & The COVID and Cancer Care-NL Consortium. Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: a population-based study. *Cancer Epidemiol*. 2023 Oct 26;87:102481. doi: 10.1016/j.canep.2023.102481. Online ahead of print.
Impactfactor: 2,6

Eijkelboom AH, Larsen M, **Siesling S**, Nygård JF, Hofvind S, **de Munck L**. Prolonged screening interval due to the COVID-19 pandemic and its association with tumor characteristics and treatment; a register-based study from BreastScreen Norway. *Prev Med*. 2023 Oct 9:107723. doi: 10.1016/j.yjmed.2023.107723. Online ahead of print.
Impactfactor: 5,1

Hamersma DT, **Schreuder K**, **Geleijnse G**, **Heeg E**, **Cellamare M**, Lobbes MB, Mureau MA, Koppert LB, Skjervén H, Nygård JF, Groothuis-Oudshoorn CG, **Siesling S**. Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics. *Breast Cancer Res Treat.* 2023 Jun 25. doi: 10.1007/s10549-023-06986-0. Online ahead of print. Impactfactor: 3,8

Huetting TA, **van Maaren MC**, **Hendriks MP**, Koffijberg H, **Siesling S**. External validation of 87 clinical prediction models supporting clinical decisions for breast cancer patients. *Breast.* 2023 Apr 17;69:382-391. doi: 10.1016/j.breast.2023.04.003. Online ahead of print. Impactfactor: 3,9

Klaassen-Dekker A, Drossaert CHC, van Maaren MC, van Leeuwen-Stok AE, Retel VP, Korevaar JC, **Siesling S**; NABOR project group. Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design. *BMC Cancer.* 2023 Nov 14;23(1):1112. doi: 10.1186/s12885-023-11504-y. Impactfactor: 3,8

Koevoets EW, Petr J, Monnikhof EM, Geerlings MI, Witlox L, van der Wall E, Stuiver MM, Sonke GS, **Velthuis MJ**, Jobsen JJ, van der Palen J, Mutsaerts HJ, de Ruiter MB, May AM, Schagen SB; PAM Study Group. Effect of physical exercise on MRI-assessed brain perfusion in chemotherapy-treated breast cancer patients: a randomized controlled trial. *J Magn Reson Imaging.* 2023 Oct 6. doi: 10.1002/jmri.28967. Online ahead of print. Impactfactor: 4,4

Lammers SW, Geurts SM, van Hellemond IE, **Swinkels AC**, Smorenburg CH, van der Sangen MJ, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FL, de Roos WK, Linn SC, Imholz AL, Smidt ML, Vriens IJ, Tjan-Heijnen VC; Dutch Breast Cancer Research Group (BOOG) For The DATA Investigators. The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. *JNCI Cancer Spectr.* 2023 Nov 22:pkad092. doi: 10.1093/jncics/pkad092. Online ahead of print. Impactfactor: 4,4

Lee SF, Shariati S, Caini S, Wong H, Chan AW, Gojsevic M, Ogita M, Ye JC, Chia D, Chao M, Sung K, Kennedy SKF, Rajeswaran T, **van den Hurk CJ**, Wolf JR, Chan RJ, Behroozian T, Bonomo P, Chow E. StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer.* 2023 Aug 9;31(9):515. doi: 10.1007/s00520-023-07983-1. Impactfactor: 3,1

Liefwaard MC, van der Voort A, van Ramshorst MS, Sanders J, Vonk S, Horlings HM, **Siesling S**, **de Munck L**, van Leeuwen AE, Kleijn M, Mitterpergher L, Kuilman MM, Glas AM, Wesseling J, Lips EH, Sonke GS. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer. *Breast Cancer Res.* 2023 Jun 19;25(1):71. doi: 10.1186/s13058-023-01664-x. Impactfactor: 7,4

Luyendijk M, Jager A, Buijs SM, **Siesling S**, Groot CAU, Blommestein HM. Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer. *Pharmacoeconomics.* 2023 May 28. doi: 10.1007/s40273-023-01277-4. Online ahead of print. Impactfactor: 4,4

Luyendijk M, Blommestein H, Uyl-de Groot C, **Siesling S**, Jager A. Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands. *JAMA Netw Open.* 2023 Feb 1;6(2):e2256170. doi: 10.1001/jamanetworkopen.2022.56170. Impactfactor: 13,8

Meurs CJ, van Bekkum S, van Rosmalen J, Menke-Pluijmers MB, **Siesling S**, Westenend PJ. ASO Visual Abstract: Validation and Clinical Utility of a Prediction Model for the Risk of Upstaging to Invasive Breast Cancer After a Biopsy Diagnosis of Ductal Carcinoma In Situ. *Ann Surg Oncol.* 2023 Aug 11. doi: 10.1245/s10434-023-14090-2. Online ahead of print. Impactfactor: 3,7

Meurs CJ, van Rosmalen J, Menke-Pluijmers MB, **Siesling S**, Westenend PJ. ASO Visual Abstract: Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model. *Ann Surg Oncol*. 2023 Jan 25. doi: 10.1245/s10434-022-13067-x. Online ahead of print.
Impactfactor: 3,7

Meurs CJ, van Bekkum S, van Rosmalen J, Menke-Pluijmers MB, **Siesling S**, Westenend PJ. Validation and Clinical Utility of a Prediction Model for the Risk of Upstaging to Invasive Breast Cancer After a Biopsy Diagnosis Ductal Carcinoma In Situ. *Ann Surg Oncol*. 2023 Aug 4. doi: 10.1245/s10434-023-13929-y. Online ahead of print.
Impactfactor: 3,7

Naaktgeboren WR, Stuiver MM, van Harten WH, Aaronson NK, Scott JM, Sonke G, van der Wall E, **Velthuis M**, Leiner T, Teske AJ, May AM, Groen WG. Effects of exercise during chemotherapy for breast cancer on long-term cardiovascular toxicity. *Open Heart*. 2023 Oct;10(2):e002464. doi: 10.1136/openhrt-2023-002464.
Impactfactor: 2,7

Nagtegaal ID, Snoek JA, Bult P, Tol J, **Siesling S**, Voorham QJ, Huguen N. The value of case reports in rare oncological scenarios: mixed method analysis of colorectal metastases from breast cancer. *Clin Exp Metastasis*. 2023 Apr 27. doi: 10.1007/s10585-023-10207-9. Online ahead of print.
Impactfactor: 4,0

Ploumen RA, Claassens EL, Kooreman LF, Keymeulen KB, van Kats MA, Gommers S, **Siesling S**, van Nijnatten TJ, Smidt ML. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis. *Breast Cancer Res Treat*. 2023 Jul 3. doi: 10.1007/s10549-023-07012-z. Online ahead of print.
Impactfactor: 3,8

Ragusi MA, van der Velden BH, Meeuwis C, Tetteroo E, Coerkamp EG, van Nijnatten TJ, Jansen FH, Wolters-van der Ben EJ, Jongen L, van Raamt F, Dorrius MD, **Verloop J**, Viergever MA, Pijnappel RM, Elias SG, Gilhuijs KG. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study. *Radiology*. 2023 Mar 28:221922. doi: 10.1148/radiol.221922. Online ahead of print.
Impactfactor: 19,7

Salvestrini V, Marta GN, Caini S, Wolf JR, **van den Hurk CJ**, Beveridge M, Lam H, Bonomo P, Chow E, Behroozian T. The effect of antiperspirant and deodorant use on acute radiation dermatitis in breast cancer patients during radiotherapy: a systematic review and meta-analysis. *Support Care Cancer*. 2023 Mar 3;31(3):198. doi: 10.1007/s00520-023-07657-y.
Impactfactor: 3,1

Schreuder K, Bult TJ, Stroop B, Koppert LB, Bijlsma RM, Bantema-Joppe EJ, Hoornweg MJ, **Siesling S**. European quality indicators developed by the European Commission Initiative on breast cancer: a first nationwide assessment for the Dutch setting. *Breast Cancer Res Treat*. 2023 Oct 26. doi: 10.1007/s10549-023-07158-w. Online ahead of print.
Impactfactor: 3,8

Shariati S, Behroozian T, Kennedy S, Caini S, Herst PM, Zhang L, Ding K, Karam I, **van den Hurk CJ**, Wolf JR, Lee SF, Wong H, Chan AW, Ogita M, Ye JC, Chan RJ, Gojsevic M, Rajeswaran T, Bonomo P, Chow E. Mepitel film for the prevention and treatment of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer*. 2023 Aug 16;31(9):524. doi: 10.1007/s00520-023-07982-2.
Impactfactor: 3,1

Steenbruggen TG, Wolf DM, Thijssen B, Sanders J, Cornelissen S, Salgado R, Mittempergher L, Bhaskaran R, Broeks A, Lips EH, **Siesling S**, Sonke GS, Horlings HM, van 't Veer LJ. Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort. *JCO Precis Oncol*. 2023 Sep;7:e2200670. doi: 10.1200/PO.22.00670.
Impactfactor: 4,6

Tjan-Heijnen VC, Lammers SW, Geurts SM, Vriens IJ, **Swinkels AC**, Smorenburg CH, van der Sangen MJ, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FL, de Roos WK, Linn SC, Imholz AL; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. *Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial.* *EClinicalMedicine.* 2023 Mar 20;58:101901. doi: 10.1016/j.eclinm.2023.101901. eCollection 2023 Apr. Impactfactor: 15,1

van Cappellen-van Maldegem SJ, **Mols F**, Seidell JC, de Kruif A, **van de Poll-Franse LV**, Hoedjes M. *Using the behavior change wheel to identify and understand key facilitators and barriers for lifestyle care for postmenopausal breast cancer survivors: a Delphi-study.* *Ann Behav Med.* 2023 Sep 6:kaad049. doi: 10.1093/abm/kaad049. Online ahead of print. Impactfactor: 3,8

van Maaren MC, **Siesling S**, Hueting TA, Völkel V, van Hezewijk M, Strobbe LJ. *The use and misuse of risk prediction tools for clinical decision-making.* *Breast.* 2023 Jan 21:S0960-9776(23)00006-1. doi: 10.1016/j.breast.2023.01.006. Online ahead of print. Impactfactor: 3,9

van Roozendaal LM, Vane ML, Colier E, Strobbe LJ, de Boer M, Sonke G, **van Maaren MC**, Smidt ML. *Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed.* *Breast Cancer Res Treat.* 2023 Oct 5. doi: 10.1007/s10549-023-07128-2. Online ahead of print. Impactfactor: 3,8

Verreck EE, van Steenhoven JE, Kuijer A, **van Maaren MC**, Simons JM, **Siesling S**, van Dalen T. *ASO Visual Abstract: Trends of Axillary Treatment in Sentinel Node-Positive Breast Cancer Patients Undergoing Mastectomy.* *Ann Surg Oncol.* 2023 Jun 15. doi: 10.1245/s10434-023-13621-1. Online ahead of print. Impactfactor: 3,7

Verreck EE, van Steenhoven JE, Kuijer A, **van Maaren MC**, Simons JM, **Siesling S**, van Dalen T. *Trends of Axillary Treatment in Sentinel Node-Positive Breast Cancer Patients Undergoing Mastectomy.* *Ann Surg Oncol.* 2023 May 24. doi: 10.1245/s10434-023-13568-3. Online ahead of print. Impactfactor: 3,7

Wang Y, Broeks A, Giardiello D, Hauptmann M, Józwiak K, Koop EA, Opdam M, **Siesling S**, Sonke GS, Stathonikos N, ter Hoeve ND, van der Wall E, van Deurzen CH, van Diest PJ, Voogd AC, Vreuls W, Linn SC, Dackus GM, Schmidt MK. *External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.* *Eur J Cancer.* 2023 Oct 30;195:113401. doi: 10.1016/j.ejca.2023.113401. Online ahead of print. Impactfactor: 8,4

Wijlens KA, Beenhakker L, Witteveen A, Siemerink EJ, Jansen L, Gernaat C, Schellekens MP, **Siesling S**, Vollenbroek-Hutten MM, Bode C. *A holistic profile for cancer-related fatigue for women with breast cancer : a qualitative study.* *Psychol Health.* 2023 Dec 18:1-25. doi: 10.1080/08870446.2023.2289457. Online ahead of print. Impactfactor: 3,3

2.2 Overige publicaties

Eijkelaarboom A, de Munck L, Siesling S. *Impact of the COVID-19 pandemic on breast incidence and stage during the COVID-19 pandemic in the Netherlands, and a comparison with other countries.* *Archives of Women Health and Care* 6(4):1-3, 2023.

van Cappellen-van Maldegem SJ, Hoedjes M, de Boer MR, Nijman IL, van Valenberg HM, Seidell JC, **van de Poll-Franse LV**, Buffart LM, **Mols F, de Rooij BH.** *Course of objectively measured physical activity and sleep in postmenopausal breast cancer survivors during the COVID-19 pandemic: a 1-year follow-up.* *Breast Dis.* 2023;42(1):415-427. doi: 10.3233/BD-230049.

van den Biggelaar YJ, Kuiper JG, van der Sangen MJ, Luiten EJ, **Siesling S**, van Herk-Sukel M, Voogd AC, Mesters I. *5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast*

cancer: a population-based database study (2006-2016). *Breast Dis.* 2023;42(1):331-339. doi: 10.3233/BD-230024.

2.3 Proefschriften en promoties

Eijkelboom AH. COVID-19 pandemic and breast cancer detection and care. Enschede: Universiteit Twente; 8 december 2023. Promotor: **S Siesling**. Copromotor: **L de Munck**.

3 Bot-en wekedelentumoren

3.1 Publicaties met impactfactor

Debets P, Dreijerink KM, Engelsman A, Dahele M, Haak HR, **Steenard RV**, Kapiteijn E, Corssmit E, Menke-van der Houven van Oordt CW. **Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study.** Eur J Cancer. 2023 Nov 10;196:113424. doi: 10.1016/j.ejca.2023.113424. Online ahead of print.
Impactfactor: 8,4

Geerling JI, van der Linden YM, **Raijmakers NJ**, Vermeulen KM, Mul VE, de Nijs EJ, Westhoff PG, de Bock GH, de Graeff A, Reyners AK. **Randomized controlled study of pain education in patients receiving radiotherapy for painful bone metastases.** Radiother Oncol. 2023 May 9:109687. doi: 10.1016/j.radonc.2023.109687. Online ahead of print.
Impactfactor: 5,7

Schut AW, de Bruin LE, **de Rooij BH**, Lidington E, Timbergen MJ, van der Graaf WT, van Houdt WJ, Bonenkamp JJ, Jones RL, Grünhagen DJ, Sleijfer S, Gennatas S, Verhoef C, Husson O. **Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare use.** Cancer Med. 2023 Apr 29. doi: 10.1002/cam4.5985. Online ahead of print.
Impactfactor: 4,0

4 Darmkanker

4.1 Publicaties met impactfactor

Bakkers C, Rovers KP, Rijken A, Simkens GA, **Bonhof CS**, Nienhuijs SW, Burger JW, Creemers GJ, Brandt-Kerkhof AR, Tuynman JB, Aalbers AG, Wiezer MJ, de Reuver PR, van Grevenstein WM, Hemmer PH, Punt CJ, Tanis PJ, **Mols F**, de Hingh IH; Dutch Peritoneal Oncology Group and the Dutch Colorectal Cancer Group. Perioperative Systemic Therapy Versus Cytoreductive Surgery and HIPEC Alone for Resectable Colorectal Peritoneal Metastases: patient-Reported Outcomes of a Randomized Phase II Trial. *Ann Surg Oncol*. 2023 Feb 8. doi: 10.1245/s10434-023-13116-z. Online ahead of print. Impactfactor: 3,7

Bakkers C, van de Vlasakker VC, Rovers KP, Lurvink RJ, Nienhuijs SW, Burger JW, Creemers GM, Bonhof CS, **Mols F**, **de Hingh IH**. The Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) versus Conventional Surgery on Patient-Reported Outcomes: a Comparative Cohort Study between the CAIRO6 Trial and the PROCORE Study. *Cancers (Basel)*. 2023 Jan 27;15(3):788. doi: 10.3390/cancers15030788. Impactfactor: 5,2

Boeding JR, **Elferink MA**, Tanis PJ, de Wilt JH, Gobardhan PD, Verhoef C, Schreinemakers JM. Surgical treatment and overall survival in patients with right-sided obstructing colon cancer: a nationwide retrospective cohort study. *Int J Colorectal Dis*. 2023 Oct 5;38(1):248. doi: 10.1007/s00384-023-04541-3. Impactfactor: 2,8

Bond MJ, Bolhuis K, Loosveld OL, de Groot JW, Droogendijk H, Helgason HH, Hendriks MP, Klaase JM, Kazemier G, Liem MS, Rijken AM, Verhoef C, de Wilt JH, de Jong KP, Gerhards MF, van Amerongen MJ, Engelbrecht MR, van Lienden KP, Molenaar IQ, de Valk B, Haberkorn BC, Kerver ED, Erdkamp F, van Alphen RJ, Mathijssen-van Stein D, **Komurcu A**, Lopez-Yurda M, Swijnenburg RJ, Punt CJ; Dutch Colorectal Cancer Study Group. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. *Lancet Oncol*. 2023 Jun 14:S1470-2045(23)00219-X. doi: 10.1016/S1470-2045(23)00219-X. Online ahead of print. Impactfactor: 51,1

Bonhof CS, **Mols F**, Widdershoven JW, **Schoormans D**. Colorectal cancer and cardiovascular disease: double the burden when it comes to your health-related quality of life? *Acta Oncol*. 2023 Jul;62(7):737-743. doi: 10.1080/0284186X.2023.2245131. Epub 2023 Aug 23. Impactfactor: 3,1

Greijdanus NG, **van Erning FN**, van Workum F, Tanis PJ, de Wilt JH, **Vissers PA**. Variation in hospital performances after colorectal cancer surgery: a case-mix adjusted Dutch population based study. *Eur J Surg Oncol*. 2023 Nov 24;50(2):107296. doi: 10.1016/j.ejso.2023.107296. Online ahead of print. Impactfactor: 3,8

Hamers PA, **Vink GR**, **Elferink MA**, Moons LM, Punt CJ, May AM, Koopman M. Impact of colorectal cancer screening on survival after metachronous metastasis. *Eur J Cancer*. 2023 Nov 12;196:113429. doi: 10.1016/j.ejca.2023.113429. Online ahead of print. Impactfactor: 8,4

Kwakman JJ, Bond MJ, Demichelis RM, Koopman M, Hompes R, **Elferink MA**, Punt CJ. Adjuvant chemotherapy in patients with clinically node-negative but pathologically node-positive rectal cancer in the Netherlands: a retrospective analysis. *Eur J Cancer*. 2023 Dec 2;197:113466. doi: 10.1016/j.ejca.2023.113466. Online ahead of print. Impactfactor: 8,4

Rijken A, Galanos LJ, Burger JW, Nienhuijs SW, **van Erning FN**, **de Hingh IH**. Peritoneal Metastases from Extraperitoneal Primary Tumors: Incidence, Treatment, and Survival from a Nationwide Database. *Indian J Surg Oncol*. 2023 Jun;14(Suppl 1):60-66. doi: 10.1007/s13193-022-01592-w. Epub 2022 Jul 20. Impactfactor: 0,5

Rijken A, van de Vlasakker VC, Simkens GA, Rovers KP, van Erning FN, Koopman M, Verhoef C, de Wilt JH, de Hingh IH. Primary tumor resection or systemic treatment as palliative treatment for patients with isolated synchronous colorectal cancer peritoneal metastases in a nationwide cohort study. *Clin Exp Metastasis*. 2023 May 20. doi: 10.1007/s10585-023-10212-y. Online ahead of print. Impactfactor: 4,0

Rijken A, Loef C, van de Wouw YA, van Erning FN, de Hingh IH. Updated Incidence, Treatment and Survival of a Nationwide Cohort of Patients with Peritoneal Metastases of Unknown Origin. *Indian J Surg Oncol*. 2023 Jun;14(Suppl 1):67-73. doi: 10.1007/s13193-022-01567-x. Epub 2022 Jun 21. Impactfactor: 0,5

Scheepers ER, Vink GR, Schiphorst AH, Emmelot-Vonk MH, van Huis-Tanja LH, Hamaker ME. Correction: Health-related quality-of-life trajectories during/after surgery and adjuvant chemotherapy in patients with colon cancer. *Eur Geriatr Med*. 2023 May 3. doi: 10.1007/s41999-023-00782-1. Online ahead of print. Impactfactor: 3,8

Scheepers ER, Vink GR, Schiphorst AHW, Emmelot-Vonk MH, van Huis-Tanja LH, Hamaker ME. Health-related quality-of-life trajectories during/after surgery and adjuvant chemotherapy in patients with colon cancer. *Eur Geriatr Med*. 2023 Mar 25. doi: 10.1007/s41999-023-00750-9. Online ahead of print. Impactfactor: 3,8

Schraa SJ, Stelloo E, Laclé MM, Swennenhuis JF, Brosens LA, Fijneman RJA, Feitsma H, Koopman M, de Leng WW, Vink GR, Bol GM. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer. *Virchows Arch*. 2023 Apr 17. doi: 10.1007/s00428-023-03538-1. Online ahead of print. Impactfactor: 3,5

Shkurti J, van den Berg K, van Erning FN, Lahaye MJ, Beets-Tan RG, Nederend J. Diagnostic accuracy of CT for local staging of colon cancer: a nationwide study in the Netherlands. *Eur J Cancer*. 2023 Aug 25;193:113314. doi: 10.1016/j.ejca.2023.113314. Online ahead of print. Impactfactor: 8,4

Sieswerda M, van Rossum R, Bermejo I, Geleijnse G, Aben KK, van Erning FN, de Hingh I, Lemmens V, Dekker A, Verbeek X. Estimating Treatment Effect of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer Using Bayesian Networks. *JCO Clin Cancer Inform*. 2023 Sep;7:e2300080. doi: 10.1200/CCI.23.00080. Impactfactor: 4,2

Swartjes H, van Rees JM, van Erning FN, Verheij M, Verhoef C, de Wilt JH, Vissers PA, Koëter T. ASO Visual Abstract: Locally Recurrent Rectal Cancer: Toward a Second Chance at Cure? a Population-Based, Retrospective, Cohort Study. *Ann Surg Oncol*. 2023 Mar 16. doi: 10.1245/s10434-023-13328-3. Online ahead of print. Impactfactor: 3,7

Swartjes H, van Rees JM, van Erning FN, Verheij M, Verhoef C, de Wilt JHW, Vissers PA, Koëter T. Locally Recurrent Rectal Cancer: Toward a Second Chance at Cure? a Population-Based, Retrospective Cohort Study. *Ann Surg Oncol*. 2023 Feb 15. doi: 10.1245/s10434-023-13141-y. Online ahead of print. Impactfactor: 3,7

Swartjes H, Qaderi SM, Teerenstra S, Custers JA, Elferink MA, van Wely BJ, Burger JW, van Grevenstein WM, van Duijvendijk P, Verdaasdonk EG, de Roos MA, Coupé VM, Vink GR, Verhoef C, de Wilt JH. Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial. *BMC Cancer*. 2023 Sep 7;23(1):838. doi: 10.1186/s12885-023-11297-0. Impactfactor: 3,8

Toes-Zoutenkijk E, Breekveldt EC, van der Schee L, Nagtegaal ID, Elferink MA, Lansdorp-Vogelaar I, Moons LM, van Leerdam ME. Differences in treatment of stage I colorectal cancers: a population-based study of colorectal cancers detected within and outside of a screening program. *Endoscopy*. 2023 Nov 7. doi: 10.1055/a-2173-5989. Online ahead of print.

Impactfactor: 9,3

van de Vlasakker VC, [Lurvink RJ](#), Wassenaar EC, Rauwerdink P, Bakkers C, Rovers KP, [Bonhof CS](#), Burger JW, Wiezer MJ, Boerma D, Nienhuijs SW, [Mols F, de Hingh IH](#). Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery. *Sci Rep*. 2023 Nov 22;13(1):20458. doi: 10.1038/s41598-023-47510-0.

Impactfactor: 4,6

van de Vlasakker VC, van den Heuvel TB, Rijken A, Nienhuijs SW, Ketelaers SH, Verrijssen AE, Rutten HJ, Nieuwenhuijzen GA, Burger JW, [de Hingh IH](#). Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with Intra-Operative Radiotherapy for Patients with Locally Advanced or Locally Recurrent Rectal Cancer and Peritoneal Metastases. *Cancers (Basel)*. 2023 Jan 30;15(3):858. doi: 10.3390/cancers15030858.

Impactfactor: 5,2

van de Vlasakker VC, [van Erning FN, Lurvink RJ, de Hingh IH](#), Nienhuijs SW. The impact of body weight on the development of peritoneal metastases in colorectal cancer patients: results from a nationwide cohort study. *World J Surg Oncol*. 2023 Oct 16;21(1):328. doi: 10.1186/s12957-023-03204-5.

Impactfactor: 3,2

[van der Ven RG](#), Westra D, [van Erning FN, de Hingh IH](#), Olde Damink SW, Paulus A, Leclercq WK, den Dulk M; OncoZON Consortium. The impact of a multi-hospital network on the inequality in odds of receiving resection or ablation for synchronous colorectal liver metastases. *Acta Oncol*. 2023 Aug 7:1-11. doi: 10.1080/0284186X.2023.2238545. Online ahead of print.

Impactfactor: 3,1

[van Erning FN, Greidanus NE, Verhoeven RH](#), Buijsen J, de Wilt HW, Wagner D, Creemers GJ. Gender differences in tumor characteristics, treatment and survival of colorectal cancer: a population-based study. *Cancer Epidemiol*. 2023 Aug 24;86:102441. doi: 10.1016/j.canep.2023.102441. Online ahead of print.

Impactfactor: 2,6

van Rees JM, Wullaert L, Grüter AA, Derraze Y, Tanis PJ, Verheul HM, Martens JW, Wilting SM, [Vink GR](#), van Vugt JLA, Beije N, Verhoef C. Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses. *Front Oncol*. 2023 Jan 30;13:1083285. doi: 10.3389/fonc.2023.1083285. eCollection 2023.

Impactfactor: 4,7

Wensink GE, Bolhuis K, [Elferink MA](#), Fijneman RJA, Kranenburg O, Borel Rinkes IH, Koopman M, Swijnenburg RJ, [Vink GR](#), Hagendoorn J, Punt CJ, Roodhart JM, Elias SG. Predicting early extrahepatic recurrence after local treatment of colorectal liver metastases. *Br J Surg*. 2023 Jan 19:znac461. doi: 10.1093/bjs/znac461. Online ahead of print.

Impactfactor: 9,6

Zwart K, van der Baan FH, Punt CJ, Wensink GE, Bolhuis K, Laclé MM, van Grevenstein WM, Hagendoorn J, [de Hingh IH](#), Koopman M, [Vink GR](#), Roodhart J. ASO Visual Abstract: Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort. *Ann Surg Oncol*. 2023 Aug 14. doi: 10.1245/s10434-023-14118-7. Online ahead of print.

Impactfactor: 3,7

Zwart K, van der Baan FH, Cohen R, Aparicio T, de la Fouchardié C, Lecomte T, Punt CJA, Sefrioui D, Verheijden RJ, [Vink GR](#), Wensink GE, Zaanen A, Koopman M, Tougeron D, Roodhart JM. Prognostic value of Lynch syndrome, BRAF^{V600E}, and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts. *Cancer Med*. 2023 Jun 16. doi: 10.1002/cam4.6223. Online ahead of print.

Impactfactor: 4,0

Zwart K, van der Baan FH, Punt CJ, Wensink GE, Bolhuis K, Laclé MM, van Grevenstein WM, Hagendoorn J, [de Hingh IH](#), Koopman M, [Vink GR](#), Roodhart J. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-

Intent Local Treatment of Metastases in a Nationwide Cohort. Ann Surg Oncol. 2023 Aug 1. doi:
10.1245/s10434-023-13974-7. Online ahead of print.
Impactfactor: 3,7

5 Gynaecologische tumoren

5.1 Publicaties met impactfactor

Algera MD, Baldewpersad Tewarie NM, Driel WJ, van Ham MA, Slangen BF, Kruitwagen RF, Wouters MW; Participants of the Dutch Gynecological Oncology Audit Collaborator Group ([van der Aa MA](#)). Case-mix adjustment to compare hospital performances regarding complications after cytoreductive surgery for ovarian cancer: a nationwide population-based study. *Int J Gynecol Cancer*. 2023 Apr 3;33(4):534-542. doi: 10.1136/ijgc-2022-003981.

Impactfactor: 4,8

Brummel B, van Heumen C, Smits A, van den Berg M, [Ezendam NP](#), Pijnenborg JM, de van der Schueren MA, Wilkinson SA, van der Meij BS. Barriers to and facilitators of a healthy lifestyle for patients with gynecological cancer: a systematic review of qualitative and quantitative research with healthcare providers and patients. *Maturitas*. 2023 Jul 22;177:107801. doi: 10.1016/j.maturitas.2023.107801. Online ahead of print.

Impactfactor: 4,9

de Decker K, [Wenzel HH](#), Bart J, [van der Aa MA](#), Kruitwagen RF, Nijman HW, Kruse AJ. Stage, treatment and survival of low-grade serous ovarian carcinoma in the Netherlands: a nationwide study. *Acta Obstet Gynecol Scand*. 2023 Feb 3. doi: 10.1111/aogs.14518. Online ahead of print.

Impactfactor: 4,3

[Ebben KC](#), de Kroon CD, Schmeink CE, [van der Hel OL](#), [van Vegchel T](#), [Moncada-Torres A](#), [de Hingh IH](#), [van der Werf J](#). A novel method for continuous measurements of clinical practice guideline adherence. *Learn Health Syst*. 2023 Sep 7;7(4):e10384. doi: 10.1002/lrh2.10384. eCollection 2023 Oct.

Impactfactor: 3,1

Fu Z, Brooks MM, Irvin S, Jordan S, [Aben KK](#), Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook LS, Cramer DW, Cushing-Haugen KL, Doherty JA, Ekici AB, Fasching PA, Fortner RT, Gayther SA, Gentry-Maharaj A, Giles GG, Goode EL, Goodman MT; AOCs Group; Harris HR, Hein A, Kaaks R, Kiemenev LA, Köbel M, Kotsopoulos J, Kotsopoulos J, Le ND, Lee AW, Matsuo K, McGuire V, McLaughlin JR, Menon U, Milne RL, Moysich KB, Pearce CL, Pike MC, Qin B, Ramus SJ, Riggan MJ, Rothstein JH, Schildkraut JM, Sieh W, Sutphen R, Terry KL, Thompson PJ, Titus L, van Altena AM, White E, Whittemore AS, Wu AH, Zheng W, Ziogas A, Taylor SE, Tang L, Songer T, Wentzensen N, Webb PM, Risch HA, Modugno F; Ovarian Cancer Association Consortium. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. *J Natl Cancer Inst*. 2023 Jan 23:djad011. doi: 10.1093/jnci/djad011. Online ahead of print.

Impactfactor: 10,3

Jeppesen MM, Bergholdt SH, Bentzen AG, [de Rooij BH](#), Skorstad M, [Ezendam NP](#), [van de Poll-Franse LV](#), Vistad I, Jensen PT. Cancer worry is associated with increased use of supportive health care-results from the multinational InCHARGE study. *J Cancer Surviv*. 2023 Jan 27. doi: 10.1007/s11764-023-01337-w. Online ahead of print.

Impactfactor: 3,7

May T, Bernardini M, Lheureux S, [Aben KK](#), Bandera EV, Beckmann MW, Benitez J, Berchuck A, Bjørge L, Carney ME, Cramer DW, deFazio A, Dörk T, Eccles DM, Friedlander M, García MJ, Goode EL, Hein A, Høgdall CK, Jensen A, Johnatty S, Kennedy CJ, Kiemenev LA, Kjær SK, Kupryjańczyk J, Matsuo K, McGuire V, Modugno F, Paddock LE, Pejovic T, Phelan CM, Riggan MJ, Rodriguez-Antona C, Rothstein JH, Sieh W, Song H, Terry KL, van Altena AM, Vanderstichele A, Vergote I, Thomsen LCV, Webb PM, Wentzensen N, Wilkens LR, Ziogas A, Jiang H, Tone A; Ovarian Cancer Association and the Australian Ovarian Cancer Study Group. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis. *Can J Surg*. 2023 Jun 27;66(3):E310-E320. doi: 10.1503/cjs.017020. Print 2023 May-Jun.

Impactfactor: 2,5

[Oymans EJ](#), de Kroon CD, Bart J, Nijman HW, [van der Aa MA](#). Incidence of gynaecological cancer during the COVID-19 pandemic: A population-based study in the Netherlands. *Cancer Epidemiol*. 2023 Jun 20;85:102405. doi: 10.1016/j.canep.2023.102405. Online ahead of print.

Impactfactor: 2,6

Said SA, de Hullu JA, [van der Aa MA](#), Walraven JE, Bekkers RL, Slangen BF, Pickkers P, van Altena AM. Impact of sepsis on the oncologic outcomes of advanced epithelial ovarian cancer patients: a multicenter observational study. *Cancers (Basel)*. 2023 Sep 20;15(18):4642. doi: 10.3390/cancers15184642.

Impactfactor: 5,2

[Schoorman MS](#), Veldmate G, Ebisch RM, de Hullu JA, [Lemmens VE](#), [van der Aa MA](#). Vulvar squamous cell carcinoma in women 80 years and older: treatment, survival and impact of comorbidities. *Gynecol Oncol*. 2023 Nov 9;179:91-96. doi: 10.1016/j.ygyno.2023.10.014. Online ahead of print.

Impactfactor: 4,7

Schoorman TN, Schaafsma M, To KH, Verhoef VM, Sikorska K, Siebers AG, [Wenzel HH](#), Bleeker MC, Roes EM, Zweemer RP, de Vos van Steenwijk PJ, Yigit R, Beltman JJ, Zusterzeel PL, Lok CA, Bekkers RL, Mom CH, van Trommel NE. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study. *Lancet Oncol*. 2023 Nov 9:S1470-2045(23)00467-9. doi: 10.1016/S1470-2045(23)00467-9. Online ahead of print.

Impactfactor: 51,1

van Kol KG, Ebisch RM, [van der Aa MA](#), [Wenzel HB](#), Piek JM, Bekkers RL. The prognostic value of the presence of pelvic and/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC). *Gynecol Oncol*. 2023 Feb 16;171:9-14. doi: 10.1016/j.ygyno.2023.01.023. Online ahead of print.

Impactfactor: 4,7

[Wenzel HH](#), Hardie AN, [Moncada-Torres A](#), Høgdall CK, Bekkers RL, Falconer H, Jensen PT, Nijman HW, [van der Aa MA](#), [Martin F](#), [van Gestel AJ](#), [Lemmens VE](#), Dahm-Kähler P, Alfonzo E, Persson J, Ekdahl L, Salehi S, Frøding LP, Markauskas A, Fuglsang K, Schnack TH. A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases. *Eur J Cancer*. 2023 Feb 26;185:61-68. doi: 10.1016/j.ejca.2023.02.021. Online ahead of print.

Impactfactor: 8,4

5.2 Overige publicaties

[Ebben K](#), [van Houdt M](#), de Kroon C, [van der Werf J](#). Guideline-Based Algorithmic Recommendations Versus Multidisciplinary Team Advice for Gynecologic Oncology. *Stud Health Technol Inform*. 2023 May 18;302:605-606. doi: 10.3233/SHTI230215.

[van Wagenveld L](#), Walker C, Hahn K, Sanders J, Kruitwagen R, [van der Aa MA](#), Sonke G, Rottenberg S, Van de Vijver K, Janowczyk A, Horlings H. The prognostic value of tumor-stroma ratio and a newly developed computer-aided quantitative analysis of routine H&E slides in high-grade serous ovarian cancer. *Res Sq*. 2023 Nov 14:rs.3.rs-3511087. doi: 10.21203/rs.3.rs-3511087/v1. Preprint.

6 Hemato-oncologie

6.1 Publicaties met impactfactor

Al-Sarayfi D, **Brink M**, Chamuleau ME, Brouwer R, van Rijn RS, Issa D, Deenik W, Huls G, Mous R, Vermaat JS, Diepstra A, Zijlstra JM, van Meerten T, Nijland M. R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity matched population-based study. *Am J Hematol*. 2023 Nov 28. doi: 10.1002/ajh.27151. Online ahead of print. Impactfactor: 12,8

Bult JA, Huisman F, Zhong Y, Veltmaat N, Kluiver J, Tonino SH, Vermaat JS, Chamuleau ME, Diepstra A, van den Berg A, Plattel WJ, **Brink M**, Nijland M. A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics. *Blood Cancer J*. 2023 Sep 1;13(1):130. doi: 10.1038/s41408-023-00903-w. Impactfactor: 12,8

de Jonge AV, van Werkhoven E, **Dinmohamed AG**, Nijland M, Zwinderman AH, Bossuyt PM, Veldhuis MS, Rutten EG, Mous R, Vermaat JS, Sandberg Y, de Jongh E, Bilgin YM, Boersma R, Koene H, Kersten MJ, de Jong D, Chamuleau ME. A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients. *Blood Cancer J*. 2023 May 22;13(1):85. doi: 10.1038/s41408-023-00854-2. Impactfactor: 12,8

Ekels A, Oerlemans S, Schagen SB, Issa DE, Thielen N, Nijziel MR, van der Poel MW, Arts LP, **Posthuma EF, van de Poll-Franse LV**. The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress. *J Cancer Surviv*. 2023 Sep 27. doi: 10.1007/s11764-023-01458-2. Online ahead of print. Impactfactor: 3,7

Geerdes EE, Durmaz M, Lugtenburg PJ, Chamuleau ME, **Visser O**, Issa DE, Brouwer RE, Posthuma EF, Zijlstra JM, Kersten MJ, **Dinmohamed AG**. No sex differential in relative survival among elderly DLBCL patients treated with R-CHOP21: a population-based study. *Blood Adv*. 2023 Jun 30 :bloodadvances.2023010480. doi: 10.1182/bloodadvances.2023010480. Online ahead of print. Impactfactor: 7,6

Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AE, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJ, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EM, Bontkes HJ, Kootstra NA, **Vogels-Nooijen S**, Rots N, van Beek J, Heemskerk MH, Groen K, van Meerten T, Mutsaers PG, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study. *EClinicalMedicine*. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. Impactfactor: 15,1

Kamphuis P, van Bergen MGJM, van Zeventer IA, de Graaf AO, **Dinmohamed AG**, Salzbrunn JB, Schuringa JJ, van der Reijden BA, Huls G, Jansen JH. Abnormal Platelet Counts and Clonal Hematopoiesis in the General Population. *Hemasphere*. 2023 Jan 5;7(1):e821. doi: 10.1097/HS9.0000000000000821. eCollection 2023 Jan. Impactfactor: 9,1

Kamphuis P, van Zeventer IA, de Graaf AO, Genovese G, Salzbrunn JB, **Dinmohamed AG**, van der Reijden BA, Schuringa JJ, Jansen JH, Huls G. Clonal hematopoiesis defined by somatic mutations infrequently co-occurs with mosaic loss of the y chromosome in a population-based cohort. *Hemasphere*. 2023 Sep 13;7(10):e956. doi: 10.1097/HS9.0000000000000956. eCollection 2023 Oct. Impactfactor: 9,1

Kamphuis P, van Zeventer IA, de Graaf AO, Salzbrunn JB, van Bergen MG, **Dinmohamed AG**, van der Reijden BA, Schuringa JJ, Jansen JH, Huls G. Sex Differences in the Spectrum of Clonal Hematopoiesis. *Hemasphere*. 2023 Jan 24;7(2):e832. doi: 10.1097/HS9.0000000000000832. eCollection 2023 Feb. Impactfactor: 9,1

Kockerols C, Valk PJ, Blijlevens NM, Cornelissen JJ, **Dinmohamed AG**, Geelen I, Hoogendoorn M, Janssen JJ, Daenen LG, Reijden BA, Westerweel PE. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population. *Eur J Haematol*. 2023 Sep 20. doi: 10.1111/ejh.14107. Online ahead of print.
Impactfactor: 3,1

Kockerols CC, Geelen IG, Levin MD, Janssen JJ, Beveloo BH, **Dinmohamed AG**, Hoogendoorn M, Cornelissen JJ, Westerweel PE. High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population. *Haematologica*. 2023 Mar 23. doi: 10.3324/haematol.2022.282447. Online ahead of print.
Impactfactor: 10,1

Lehmann J, de Ligt KM, Tipelius S, Giesinger JM, Sztankay M, Voigt S, **van de Poll-Franse LV**, Rumpold G, Weger R, Willenbacher E, Willenbacher W, Holzner B. Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: longitudinal Observational Study. *J Med Internet Res*. 2023 Aug 22;25:e46017. doi: 10.2196/46017.
Impactfactor: 7,4

Lindman A, Handberg C, Olesen G, **Duijts S**. A multimodal interdisciplinary rehabilitation programme (HAPPY) for patients undergoing allogeneic non-myeloablative haematopoietic stem cell transplantation: a feasibility study. *Eur J Oncol Nurs*. 2023 May 11;65:102339. doi: 10.1016/j.ejon.2023.102339. Online ahead of print.
Impactfactor: 2,8

Meeuwes FO, **Brink M**, Plattel W, van der Poel MW, Kersten MJ, Wondergem M, Böhmer L, Woei-A-Jin FJ, Visser O, Oostvogels R, Jansen PM, Neelis KJ, Crijns AP, Daniëls LA, Sniijders TJ, Vermaat JS, Huls GA, Nijland M. Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma: a nationwide population-based cohort study from the Netherlands. *Haematologica*. 2023 Oct 5. doi: 10.3324/haematol.2023.283174. Online ahead of print.
Impactfactor: 10,1

Oerlemans S, Efficace F, Shamieh O, Cardoso Borges F, de Jong C, Dong D, Lehmann J, Malak S, Petranovic D, Scholz CW, Caocci G, Molica S, Griskevicius L, Nagele E, Bredart A, Carvalho EL, Xochelli A, Agelink van Rentergem JA, Alrijoub WI, Mueller A, Freitas AC, Cocks K, Creutzberg CL, Kyriakou C, **van de Poll-Franse LV**. International validation of a health-related quality of life questionnaire for Hodgkin Lymphoma: the EORTC QLQ-HL27. *Blood Adv*. 2023 Sep 22: bloodadvances. 2023010841. doi: 10.1182/bloodadvances.2023010841. Online ahead of print.
Impactfactor: 7,6

Oerlemans S, Efficace F, Kyriakou C, Freitas AC, Shamieh O, Creutzberg CL, Lehmann J, Petranovic D, Nagele E, Bredart A, Dong D, Scholz CW, Caocci G, Molica S, Griskevicius L, Xochelli A, Kieffer JM, Agelink van Rentergem JA, Alrijoub W, Mueller A, Gomes Da Silva M, Alves da Costa F, Malak S, Cocks K, **van de Poll-Franse LV**; EORTC Quality of Life Group. International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkin lymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkin lymphoma (QLQ-NHL-LG20). *Cancer*. 2023 May 19. doi: 10.1002/cncr.34822. Online ahead of print.
Impactfactor: 6,2

Schulpen M, Beishuizen A, Chamuleau ME, **Dinmohamed AG**, Meyer-Wentrup FA, Vormoor HJ, Van der Wagen LE, Minnema MC, Loeffen JL, **Karim-Kos HE**. Survival disparities between children and adolescents and young adults for the major subtypes of non-Hodgkin lymphoma in the Netherlands: a large population-based study. *Haematologica*. 2023 Aug 31. doi: 10.3324/haematol.2023.283379. Online ahead of print.
Impactfactor: 10,1

Sijs-Szabo A, **Dinmohamed AG**, Versluis J, van der Holt B, Bellido M, Hazenberg MD, van Gelder M, Schaap NP, Meijer E, van der Wagen LE, Halkes CJ, Rijnveld AW, Cornelissen JJ. Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning. *Transplantation*. 2023 Jun 30. doi: 10.1097/TP.0000000000004706. Online ahead of print.

Impactfactor: 6,2

van der Straten L, Levin MD, **Dinnessen MA**, **Visser O**, Posthuma EFM, Doorduijn JK, Langerak AW, Kater AP, **Dinmohamed AG**. Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. *Blood Cancer J.* 2023 Jan 13;13(1):15. doi: 10.1038/s41408-023-00784-z.

Impactfactor: 12,8

van Lieshout R, Tick LW, de Beer F, Koene HR, Regelink JC, Westerweel PE, de Witte MA, Beckers EA, Schouten HC, **Beijer S**. Medical nutrition therapy during intensive remission-induction treatment and hematopoietic stem cell transplantation in acute myeloid leukemia patients: Hematologists' experiences and perspectives. *Clin Nutr ESPEN.* 2023 Oct;57:399-409. doi: 10.1016/j.clnesp.2023.07.015. Epub 2023 Jul 18.

Impactfactor: 3,0

van Zeventer IA, de Graaf AO, Salzbrunn JB, Nolte IM, Kamphuis P, **Dinmohamed AG**, van der Reijden BA, Schuringa JJ, Jansen JH, Huls G. Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population. *Cancer Cell.* 2023 May 3:S1535-6108(23)00132-0. doi: 10.1016/j.ccell.2023.04.006. Online ahead of print.

Impactfactor: 50,3

7 Hoofdhalskanker

7.1 Publicaties met impactfactor

Botta L, Matsuda T, Charvat H, Chiang CJ, Lee WC, **van Gestel AJ, Martin F, Geleijnse G, Cellamare M**, Bonfarnuzzo S, Marcos-Gragera R, Guevara M, Mousavi M, Craig S, Rodrigues J, Rubió-Casadevall J, Licitra L, Cavalieri S, Resteghini C, Gatta G, Trama A; RARECAREnet working group. Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure. *Front Oncol.* 2023 Sep 13;13:1219111. doi: 10.3389/fonc.2023.1219111. eCollection 2023. Impactfactor: 4,7

Lee SF, Wong HC, Chan AW, Caini S, Shariati S, Rades D, Chan RJ, Kennedy SK, Wolf JR, van den **Hurk CJ**, Behroozian T, Bonomo P, Ho FCH, Chow E, Herst P. Mepitel Film for the prevention of acute radiation dermatitis in head and neck cancer: a systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer.* 2023 Aug 18;31(9):527. doi: 10.1007/s00520-023-07988-w. Impactfactor: 3,1

Mols F, Schoormans D, Netea-Maier R, Husson O, **Beijer S**, Van Deun K, Zandee W, Kars M, Wouters van Poppel PC, Simsek S, van Battum P, Kisters JM, de Boer JP, Massolt E, van Leeuwen R, Oranje W, Roerink S, Vermeulen M, **van de Poll-Franse LV**. Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study. *Thyroid Res.* 2023 Jul 10;16(1):23. doi: 10.1186/s13044-023-00165-5. Impactfactor: 2,2

van Beers MA, Schreuder WH, Balm AJ, **van Dijk BA**. Is locally advanced head and neck cancer 'increasing' in the Netherlands? The paradox of absolute numbers, standardized incidence rates and proportional share. *Oral Oncol.* 2023 Jan 27;138:106316. doi: 10.1016/j.oraloncology.2023.106316. Online ahead of print. Impactfactor: 4,8

van de Weerd C, **van Dijk BA, Merx MA**, Takes RP, **Brands MT**. A nationwide study on cancer recurrences, second primary tumours, distant metastases and survival after treatment for primary head and neck cancer in the Netherlands. *Eur J Surg Oncol.* 2023 Mar 17:S0748-7983(23)00380-3. doi: 10.1016/j.ejso.2023.03.209. Online ahead of print. Impactfactor: 3,8

van den Bovenkamp K, van der Vegt B, Halmos GB, Slagter-Menkema L, Langendijk JA, **van Dijk BA**, Schuurung E, van der Laan BF. The relation between hypoxia and proliferation biomarkers with radiosensitivity in locally advanced laryngeal cancer. *Eur Arch Otorhinolaryngol.* 2023 Apr 8. doi: 10.1007/s00405-023-07951-9. Online ahead of print. Impactfactor: 2,6

van der Kamp MF, Hiddingh E, de Vries J, **van Dijk BA**, Schuurung E, Slagter-Menkema L, van der Vegt B, Halmos GB. Association of Tumor Microenvironment with Biological and Chronological Age in Head and Neck Cancer. *Cancers (Basel).* 2023 Jul 28;15(15):3834. doi: 10.3390/cancers15153834. Impactfactor: 5,2

8 Huidkanker

8.1 Publicaties met impactfactor

Boer FL, **Ho VK**, **Louwman MW**, Schrader AM, Zuur CL, Blank CU, van Poelgeest MI, Kapiteijn EH. Trends in Incidence and Survival of 1496 Patients with Mucosal Melanoma in The Netherlands (1990-2019). *Cancers (Basel)*. 2023 Feb 28;15(5):1541. doi: 10.3390/cancers15051541. Impactfactor: 5,2

Cook S, Pethick J, Kibbi N, **Hollestein L**, Lavelle K, de Vere Hunt I, Turnbull C, Rous B, Husain A, Burn J, Lüchtenborg M, Santaniello F, McRonald F, Hardy S, Linos E, Venables Z, Rajan N. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018. *J Am Acad Dermatol*. 2023 Dec;89(6):1129-1135. doi: 10.1016/j.jaad.2023.03.046. 21:S0190-9622(23)03039-6. doi: 10.1016/j.jaad.2023.10.036. Online ahead of print. Impactfactor: 13,8

Egeler MD, van Leeuwen M, Fraterman I, van den Heuvel NM, Boekhout AH, Lai-Kwon J, Wilthagen EA, Eriksson H, Haanen JB, Wilgenhof S, Ascierto PA, van Akkooi AC, **van de Poll-Franse LV**. Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: a systematic scoping review. *Crit Rev Oncol Hematol*. 2023 Feb 1;183:103919. doi: 10.1016/j.critrevonc.2023.103919. Online ahead of print. Impactfactor: 6,2

Egeler MD, **van de Poll-Franse LV**, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hoppers GA, de Groot JW, Aarts MJ, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KP, Neyns B, Janssen KJ, Blank CU, Retèl VP, Boekhout AH. Health-state utilities in long-term advanced melanoma survivors comparable with the general population. *Qual Life Res*. 2023 Apr 20. doi: 10.1007/s11136-023-03427-9. Online ahead of print. Impactfactor: 3,5

Egeler MD, Boomstra E, Rohaan MW, Van den Heuvel NM, Fraterman I, Delfos M, **van de Poll-Franse LV**, Borch TH, Svane IM, Haanen JB, Retèl VP, Boekhout AH. "One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care. *J Cancer Surviv*. 2023 Aug 22. doi: 10.1007/s11764-023-01452-8. Online ahead of print. Impactfactor: 3,7

Eggermont C, **Hollestein L**, Hollatz A, **Louwman M**, Mooyaart A, Nijsten T, Wakkee M. Cumulative incidence and timing of subsequent cutaneous squamous cell carcinomas stratified for patients with organ transplantation and hematologic malignancies: a nationwide cohort study. *J Am Acad Dermatol*. 2023 Oct 21:S0190-9622(23)03039-6. doi: 10.1016/j.jaad.2023.10.036. Online ahead of print. Impactfactor: 13,8

Eggermont C, Nené LE, Koekelkoren FH, van der Toorn YR, Snetselaar LD, Kroah-Hartman M, Genders RE, Kelleners-Smeets NW, **Hollestein LM**, van Kester MS, Wakkee M. The Impact of Routine Ultrasonography on Nodal Metastasis in Head and Neck Cutaneous Squamous Cell Carcinoma: A Retrospective Multi-center Cohort Study. *J Eur Acad Dermatol Venereol*. 2023 Apr 28. doi: 10.1111/jdv.19150. Online ahead of print. Impactfactor: 9,2

Fraterman I, Wollersheim BM, Tibollo V, Glaser SLC, Medlock S, Cornet R, Gabetta M, Gisko V, Barkan E, di Flora N, Glasspool D, Kogan A, Lanzola G, Leizer R, Mallo H, Ottaviano M, Peleg M, **van de Poll-Franse LV**, Veggiotti N, Śniatała K, Wilk S, Parimbelli E, Quaglini S, Rizzo M, Locati LD, Boekhout A, Sacchi L, Wilgenhof S. An eHealth App (CAPABLE) providing symptom monitoring, well-being interventions, and educational material for patients with melanoma treated with immune checkpoint inhibitors: protocol for an exploratory intervention trial. *JMIR Res Protoc*. 2023 Oct 11;12:e49252. doi: 10.2196/49252. Impactfactor: 1,7

Fraterman I, Reijers IL, Dimitriadis P, Broeks A, Gonzalez M, Menzies AM, Lopez-Yurda M, Kapiteijn E, van der Veldt AA, Suijkerbuijk KP, Hospers GA, Long GV, Blank CU, **van de Poll-Franse LV**. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. *Nat Med*. 2023 Nov 13. doi: 10.1038/s41591-023-02631-x. Online ahead of print. Impactfactor: 82,9

Neale RE, Lucas RM, Byrne SN, **Hollestein L**, Rhodes LE, Yazar S, Young AR, Berwick M, Ireland RA, Olsen CM. The effects of exposure to solar radiation on human health. *Photochem Photobiol Sci*. 2023 Mar 1. doi: 10.1007/s43630-023-00375-8. Online ahead of print. Impactfactor: 3,1

Padilla CS, Ho VK, Mooijenkint TW, Louwman MW, de Vos FY, Bekkenk MW, Minnaard WA, **Loef C**, van Zanten SE. Brain metastases in adult patients with melanoma of unknown primary in the Netherlands (2011-2020). *J Neurooncol*. 2023 May 12. doi: 10.1007/s11060-023-04335-1. Online ahead of print. Impactfactor: 3,9

Rentroia-Pacheco B, Tokez S, Bramer EM, Venables ZC, van de Werken HJ, Bellomo D, van Klaveren D, Mooyaart AL, **Hollestein LM**, Wakkee M. Personalised decision making to predict absolute metastatic risk in cutaneous squamous cell carcinoma: development and validation of a clinico-pathological model. *EClinicalMedicine*. 2023 Aug 19;63:102150. doi: 10.1016 /j.eclinm.2023.102150. eCollection 2023 Sep. Impactfactor: 15,1

van Lith PE, Schreuder K, Jalving M, Reyners AK, Been LB, Rácz E, **Fransen HP, Louwman MW**. Systemic therapy timing and use in patients with advanced melanoma at the end of life: a retrospective cohort study. *J Dermatol*. 2023 Dec 11. doi: 10.1111/1346-8138.17061. Online ahead of print. Impactfactor: 3,1

9 Longkanker

9.1 Publicaties met impactfactor

Billingsy NE, Tromp V, Aaronson NK, Hoek RJ, Bogaard HJ, Onwuteaka-Philipsen BD, [van de Poll-Franse LV](#), Hugtenburg JG, Belderbos J, Becker-Commissaris A, [van den Hurk CJ](#), Walraven I; SYMPRO-Lung Consortium. Quality of life after patient-initiated versus physician-initiated response to symptom monitoring: the SYMPRO-Lung trial. *J Natl Cancer Inst.* 2023 Aug 21:djad159. doi: 10.1093/jnci/djad159. Online ahead of print. Impactfactor: 10,3

Dumoulin DW, [Aarts MJ](#), De Ruyscher D, Aerts JG, Dingemans AC. Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989-2020. *Eur J Cancer.* 2023 Jul 13;191:112985. doi: 10.1016/j.ejca.2023.112985. Online ahead of print. Impactfactor: 8,4

Gijtenbeek RG, [Damhuis RA](#), van der Wekken AJ, Hendriks LE, Groen HJ, van Geffen WH. Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study. *Lancet Reg Health Eur.* 2023 Feb 6;27:100592. doi: 10.1016/j.lanep.2023.100592. eCollection 2023 Apr. Impactfactor: 20,9

Klarenbeek SE, [Aarts MJ](#), van den Heuvel MM, Prokop M, Tummers M, Schuurbiens-Siebers OC. Impact of time-to-treatment on survival for early-stage non-small cell lung cancer in The Netherlands: a nationwide observational cohort study. *Transl Lung Cancer Res.* 2023 Oct 31;12(10):2015-2029. doi: 10.21037/tlcr-23-256. Epub 2023 Oct 9. Impactfactor: 4,0

[Swart EM](#), Noordhof AL, [Damhuis RA](#), [Kunst PW](#), De Ruyscher DK, Hendriks LE, van Geffen WH, [Aarts MJ](#). Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors. *Lung Cancer.* 2023 Jul 1;182:107290. doi: 10.1016/j.lungcan.2023.107290. Online ahead of print. Impactfactor: 5,3

ten Berge DM, [Damhuis RA](#), Aerts JG, Dingemans AC. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands. *Lung Cancer.* 2023 May 18;181:107253. doi: 10.1016/j.lungcan.2023.107253. Online ahead of print. Impactfactor: 5,3

9.2 Overige publicaties

Noordhof AL, [Swart EM](#), [Damhuis RA](#), Hendriks LE, Kunst PW, [Aarts MJ](#), van Geffen WH. Prognostic Implication of KRAS G12C mutation in a real-world KRAS-Mutated Stage IV NSCLC cohort treated with immunotherapy in The Netherlands. *JTO Clin Res Rep.* 2023 Jun 29;4(9):100543. doi: 10.1016/j.jtocrr.2023.100543. eCollection 2023 Sep.

10 Neuro-oncologie

10.1 Publicaties met impactfactor

Albers EA, de Ligt KM, [van de Poll-Franse LV](#), Compter A, de Ruiten MB, Schagen SB. Health-related quality of life after stereotactic radiosurgery in patients with brain metastases. *Support Care Cancer*. 2023 Nov 27;31(12):720. doi: 10.1007/s00520-023-08203-6. Impactfactor: 3,1

[Ho VK](#), Anten MM, [Garst A](#), Bos EM, Snijders TJ, Eekers DB, Seute T; Dutch Brain Tumour Registry (DBTR) and the Dutch Society for Neuro-Oncology (LWNO). *Epidemiology of adult meningioma: report from the Dutch Brain Tumour Registry (2000-2019)*. *Eur J Neurol*. 2023 Jul 11. doi: 10.1111/ene.15979. Online ahead of print. Impactfactor: 5,1

Hoogendijk R, van der Lugt J, Baugh J, Kline C, Kranendonk M, Hoving E, Kremer L, Wesseling P, [Karim-Kos H](#), van Vuurden D. Sex-related incidence and survival differences in pediatric high-grade glioma subtypes: a population-based cohort study. *iScience*. 2023 Sep 17;26(10):107957. doi: 10.1016/j.isci.2023.107957. eCollection 2023 Oct 20. Impactfactor: 5,8

Zegers AD, Coenen P, [Heeren A](#), [Takke N](#), Ardon H, Compter A, Dona D, Kouwenhoven M, Schagen SB, de Vos F, [Duijts SF](#). Work-related experiences and unmet needs of patients with a malignant glioma and relevant professionals: the BrainWork study. *J Cancer Surviv*. 2023 Oct 2. doi: 10.1007/s11764-023-01469-z. Online ahead of print. Impactfactor: 3,7

11 Upper GI & HPB

11.1 Publicaties met impactfactor

Augustinus S, Schafrat PJ, Janssen BV, Bonsing BA, Brosens LA, Busch OR, Crobach S, Doukas M, van Eijck CH, [van der Geest LG](#), Groot Koerkamp B, de Hingh IH, Raicu GM, van Santvoort HC, van Velthuysen ML, Verheij J, Besselink MG, Farina Sarasqueta A; Dutch Pancreatic Cancer Group. *ASO Visual Abstract: Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer*. *Ann Surg Oncol*. 2023 May 19. doi: 10.1245/s10434-023-13555-8. Online ahead of print.

Impactfactor: 3,7

Augustinus S, Schafrat PJ, Janssen BV, Bonsing BA, Brosens LA, Busch OR, Crobach S, Doukas M, van Eijck CH, [van der Geest LG](#), Groot Koerkamp B, de Hingh IH, Raicu GM, van Santvoort HC, van Velthuysen ML, Verheij J, Besselink MG, Farina Sarasqueta A; Dutch Pancreatic Cancer Group. *Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival in Pancreatoduodenectomy for Pancreatic Cancer*. *Ann Surg Oncol*. 2023 May 20. doi: 10.1245/s10434-023-13465-9. Online ahead of print.

Impactfactor: 3,7

Doeve BH, [Bakx JA](#), Siersema PD, Rosman C, van Grieken NC, van Berge Henegouwen MI, van Sandick JW, Verheij M, Bijlsma MF, [Verhoeven RH](#), van Laarhoven HW. *The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer*. *J Gastroenterol*. 2023 Jul 31. doi: 10.1007/s00535-023-02009-3. Online ahead of print.

Impactfactor: 6,3

Gertsen EC, van der Veen A, Brenkman HJ, Brosens LA, van der Post RS, [Verhoeven RH](#), [Luijten JC](#), [Vissers PA](#), Vegt E, van Hillegersberg R, Siersema PD, Ruurda JP. *Multimodal therapy versus primary surgery for gastric and gastroesophageal junction diffuse type carcinoma, with a focus on signet ring cell carcinoma: a nationwide study*. *Ann Surg Oncol*. 2023 Dec 21. doi: 10.1245/s10434-023-14690-y. Online ahead of print.

Impactfactor: 3,7

Graus MU, de Hingh IH, Besselink MG, Bruno MJ, Wilmink JW, de Meijer VE, van Velthuysen MF, Valkenburg-van Iersel LB, [van der Geest LG](#), de Vos-Geelen J; Dutch Pancreatic Cancer Group (DPCG) and the COVID & Cancer-NL consortium; Dutch Nationwide Pathology Databank (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, PALGA); SONCOS (Dutch Multidisciplinary Oncology Foundation) ([van Hooft JC](#), [Merkx MA](#)). *Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer*. *HPB (Oxford)*. 2023 May 6:S1365-182X(23)00134-X. doi: 10.1016/j.hpb.2023.04.017. Online ahead of print.

Impactfactor: 2,9

[Ho VK](#), Deijen CL, [Hemmes B](#), [van Erning FN](#), Snaebjornsson P, van Triest B, Grotenhuis BA. *Trends in epidemiology and primary treatment of anal squamous cell carcinoma in the Netherlands (1990-2021)*. *Int J Cancer*. 2023 Dec 27. doi: 10.1002/ijc.34811. Online ahead of print.

Impactfactor: 6,4

Hopstaken JS, [Vissers PA](#), Quispel R, de Vos-Geelen J, Brosens LA, de Hingh IH, [van der Geest LG](#), Besselink MG, van Laarhoven KJ, Stommel MW. *Impact of network treatment in patients with resected pancreatic cancer on use and timing of chemotherapy and survival*. *BJS Open*. 2023 May 5;7(3):zrad006. doi: 10.1093/bjsopen/zrad006.

Impactfactor: 3,2

Kalff MC, [Dijksterhuis WP](#), Wagner AD, Oertelt-Prigione S, [Verhoeven RH](#), [Lemmens VE](#), van Laarhoven HW, Gisbertz SS, van Berge Henegouwen MI. *Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: a population-based study*. *Eur J Cancer*. 2023 Apr 8;187:114-123. doi: 10.1016/j.ejca.2023.04.002. Online ahead of print.

Impactfactor: 8,4

Keywani K, Borgstein AB, Eshuis WJ, **Pape M**, Versteeg KS, Derks S, van Laarhoven HW, Gisbertz SS, **Verhoeven RH**, van Berge Henegouwen MI. Neoadjuvant chemotherapy in older patients with gastric cancer undergoing surgery: a population-based cohort study. *Gastric Cancer*. 2023 Jun 7. doi: 10.1007/s10120-023-01404-2. Online ahead of print. Impactfactor: 7,4

Klatte DC, Boekestijn B, Onnekink AM, Dekker FW, **van der Geest LG**, Wasser MN, Feshtali SS, Mieog JS, Luelmo SA, Morreau H, Potjer TP, Inderson A, Boonstra JJ, Vasen HF, van Hooft JE, Bonsing BA, van Leerdam ME; Dutch Pancreatic Cancer Group. Surveillance for pancreatic cancer in high-risk individuals leads to improved outcomes: a propensity score-matched analysis. *Gastroenterology*. 2023 Mar 6:S0016-5085(23)00218-4. doi: 10.1053/j.gastro.2023.02.032. Online ahead of print. Impactfactor: 29,4

Kuijper SC, Besseling J, Klausch T, Slingerland M, van der Zijden CJ, Kouwenhoven EA, Beerepoot LV, Mohammad NH, Klarenbeek BR, **Verhoeven RH**, van Laarhoven HW. Assessing real-world representativeness of prospective registry cohorts in oncology: insights from patients with esophagogastric cancer. *J Clin Epidemiol*. 2023 Oct 21:S0895-4356(23)00269-X. doi: 10.1016/j.jclinepi.2023.10.009. Online ahead of print. Impactfactor: 7,2

Kuijper SC, **Pape M**, **Vissers PA**, Jeene PM, Kouwenhoven EA, Haj Mohammad N, Ruurda JP, Sosef MN, **Verhoeven RH**, van Laarhoven HW. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study. *Int J Cancer*. 2023 Mar 1. doi: 10.1002/ijc.34488. Online ahead of print. Impactfactor: 6,4

Luijten JC, **Vissers PA**, Geerts J, **Lemmens VE**, van Hillegersberg R, Beerepoot L, Walraven JE, Curvers W, Voncken FE, van der Sangen M, **Verhoeven RH**, Nieuwenhuijzen GA. Hospital practice variation in the proportion of patients with esophagogastric cancer discussed during an expert multidisciplinary team meeting. *Eur J Surg Oncol*. 2023 Mar 15:S0748-7983(23)00387-6. doi: 10.1016/j.ejso.2023.03.216. Online ahead of print. Impactfactor: 3,8

Luijten JC, Verstegen MH, van Workum F, Nieuwenhuijzen GA, van Berge Henegouwen MI, Gisbertz SS, Wijnhoven BP, **Verhoeven RH**, Rosman C. Survival after Ivor Lewis versus McKeown esophagectomy for cancer: propensity score matched analysis. *Dis Esophagus*. 2023 Jan 6:doac100. doi: 10.1093/dote/doac100. Online ahead of print. Impactfactor: 2,6

Noordzij IC, Hazen ML, Nieuwenhuijzen GA, **Verhoeven RH**, Schoon EJ. Endoscopic therapy replaces surgery for clinical T1 oesophageal cancer in the Netherlands: a nationwide population-based study. *Surg Endosc*. 2023 Feb 27. doi: 10.1007/s00464-023-09914-x. Online ahead of print. Impactfactor: 3,1

Olthof PB, Franssen S, van Keulen AM, **van der Geest LG**, Hoogwater FJ Coenraad M, van Driel LM, Erdmann JI, Mohammad NH, Heij L, Klümpen HJ, Tjwa E, Valkenburg-van Iersel L, Verheij J, Groot Koerkamp B; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG). Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. *HPB (Oxford)*. 2023 Jul 17:S1365-182X(23)00584-1. doi: 10.1016/j.hpb.2023.06.019. Online ahead of print. Impactfactor: 2,9

Pape M, **Vissers PA**, Kato K, Haj Mohammad N, Klarenbeek B, van Laarhoven HW, Matsuda T, **Verhoeven RH**. A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands. *J Cancer Res Clin Oncol*. 2023 Jul 24. doi: 10.1007/s00432-023-05111-4. Online ahead of print. Impactfactor: 3,6

Pape M, **Vissers PA**, **Dijksterhuis WP**, Bertwistle D, McDonald L, Mostert B, Derks S, Oving IM, **Verhoeven RH**, van Laarhoven HW. Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. *Ther Adv Med Oncol*. 2023 Mar 21;15:17588359231162576. doi: 10.1177/17588359231162576.

Impactfactor: 4,9

Pape M, Kuijper SC, **Vissers PA**, Ruurda JP, Neelis KJ, van Laarhoven HW, **Verhoeven RH**. Conditional relative survival in non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study. *Int J Cancer*. 2023 Feb 25. doi: 10.1002/ijc.34480. Online ahead of print.

Impactfactor: 6,4

Pape M, Veen LM, Smit TM, **Kuijper SC**, **Vissers PA**, Geijsen ED, van Rossum PS, Sprangers MA, Derks S, **Verhoeven RH**, van Laarhoven HW. Late toxicity and health-related quality of life following definitive chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. *Int J Radiat Oncol Biol Phys*. 2023 May 22:S0360-3016(23)00512-6. doi: 10.1016/j.ijrobp.2023.05.025. Online ahead of print.

Impactfactor: 7,0

Pape M, **Vissers PA**, Slingerland M, Haj Mohammad N, van Rossum PS, **Verhoeven RH**, van Laarhoven HW; Dutch Upper GI Cancer Group (DUCG). Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy. *Support Care Cancer*. 2023 Aug 14;31(9):520. doi: 10.1007/s00520-023-07963-5.

Impactfactor: 3,1

Rijken A, Bakkers C, Klumpen HJ, **van der Geest LG**, de Vos-Geelen J, **van Erning FN**, **de Hingh IH**. Insights into synchronous peritoneal metastases from hepatobiliary origin: Incidence, risk factors, treatment, and survival from a nationwide database. *Eur J Surg Oncol*. 2023 Mar 5:S0748-7983(23)00175-0. doi: 10.1016/j.ejso.2023.03.004. Online ahead of print.

Impactfactor: 3,8

Rijken A, **Pape M**, Simkens GA, **de Hingh IH**, Luyer MD, van Sandick JW, van Laarhoven HW, **Verhoeven RH**, **van Erning FN**. Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival. *Int J Cancer*. 2023 Nov 2. doi: 10.1002/ijc.34780. Online ahead of print.

Impactfactor: 6,4

van Dooren M, de Savornin Lohman EA, Brekelmans E, **Vissers PA**, Erdmann JI, Braat AE, Hagendoorn J, Daams F, van Dam RM, de Boer MT, van den Boezem PB, Koerkamp BG, de Reuver PR. The diagnostic value of staging laparoscopy in gallbladder cancer: a nationwide cohort study. *World J Surg Oncol*. 2023 Jan 14;21(1):6. doi: 10.1186/s12957-022-02880-z.

Impactfactor: 3,2

van Erning FN, **Vissers PA**. ASO Author Reflections: Gastrointestinal symptoms after esophagectomy or gastrectomy do not represent a temporary problem. *Ann Surg Oncol*. 2023 Jul 25. doi: 10.1245/s10434-023-13958-7. Online ahead of print.

Impactfactor: 3,7

van Erning FN, Nieuwenhuijzen GA, van Laarhoven HW, Rosman C, Gisbertz SS, Heisterkamp J, Lagarde SM, Slingerland M, van den Berg JW, Kouwenhoven EA, **Verhoeven RH**, **Vissers PA**. ASO Visual Abstract: gastrointestinal symptoms after resection of esophagogastric cancer: a longitudinal study on their incidence and impact on patient-reported outcomes. *Ann Surg Oncol*. 2023 Aug 25. doi: 10.1245/s10434-023-14102-1. Online ahead of print.

Impactfactor: 3,7

van Erning FN, Nieuwenhuijzen GP, van Laarhoven HW, Rosman C, Gisbertz SS, Heisterkamp J, Lagarde SM, Slingerland M, van den Berg JW, Kouwenhoven EA, **Verhoeven RH**, **Vissers PA**. Gastrointestinal Symptoms After Resection of Esophagogastric Cancer: A Longitudinal Study on Their Incidence and Impact on Patient-Reported Outcomes. *Ann Surg Oncol*. 2023 Jul 31. doi: 10.1245/s10434-023-13952-z. Online ahead of print.

Impactfactor: 3,7

van Velzen MJ, Braemer M, Nieuwenhuijzen GA, van Sandick JW, Siersema PD, Ruurda JP, Verheij M, Spaander MC, Beerepoot LV, Haj Mohammad N, van Laarhoven HW, **Verhoeven RH**. Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer. *JAMA Netw Open*. 2023 Aug 1;6(8):e2330018. doi: 10.1001/jamanetworkopen.2023.30018.

Impactfactor: 13,8

Vissers PA, Luijten JC, Lemmens VE, van Laarhoven HW, Slingerland M, Wijnhoven BP, Rosman C, Mook S, Heisterkamp J, Hendriksen EM, Gisbertz SS, Nieuwenhuijzen GA, **Verhoeven RH**. The association between hospital variation in curative treatment for esophagogastric cancer and health-related quality of life and survival. Eur J Surg Oncol. 2023 Aug 12;49(10):107019. doi: 10.1016/j.ejso.2023.107019. Online ahead of print. Impactfactor: 3,8

11.2 Proefschriften en promoties

Pape M. Beyond clinical trials: population-based outcomes of patients with esophagogastric cancer. Amsterdam: Universiteit Amsterdam; 9 juni 2023. Promotor: HW van Laarhoven. Copromotores: **RH Verhoeven, PA Vissers**. Overige leden: JW Wilmink, BP Wijnhoven, JJ Bergman, SS Gisbertz, EC Gootjes, **VE Lemmens**.

12 Urogenitale kanker

12.1 Publicaties met impactfactor

Beeren I, Klerks NE, **Aben KK**, Oddens JR, Witjes JA, Kiemeney LA, Vrieling A. Health-related quality of life during the first 4 years after non-muscle-invasive bladder cancer diagnosis: results of a large multicentre prospective cohort. *Eur Urol Oncol*. 2023 Nov 22:S2588-9311(23)00252-3. doi: 10.1016/j.euo.2023.11.007. Online ahead of print.

Impactfactor: 8,2

Brück K, Meijer RP, Boormans JL, Kiemeney LA, Witjes JA, **van Hoogstraten LM**, van der Heijden MS, Donders AR, Franckena M, de Groot CA, Leliveld AM, **Aben KK**, Hulshof MC; CRAC study group and the BLAZIB study group. Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study. *Int J Radiat Oncol Biol Phys*. 2023 Jul 28:S0360-3016(23)07686-1. doi: 10.1016/j.ijrobp.2023.07.027.

Impactfactor: 7,0

Brück K, **Aben KK**, Hulshof MC. In reply to Hasan et al. *Int J Radiat Oncol Biol Phys*. 2024 Jan 1;118(1):310-311. doi: 10.1016/j.ijrobp.2023.09.028.

Impactfactor: 7,0

de Haar-Holleman A, **van Hoogstraten LM**, Hulshof MC, Tascilar M, **Brück K**, Meijer RP, Witjes JA, Kiemeney LA, **Aben KK**; BlaZIB study group. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study. *Radiother Oncol*. 2023 Feb 28:109584. doi: 10.1016/j.radonc.2023.109584. Online ahead of print.

Impactfactor: 5,7

Faessen JP, Oerlemans DJ, de Jong MR, Overbeek JA, **Vissers PA**, **Aben KK**, Janssen-Heijnen ML, van den Bergh JP, van Osch FH. The association between diabetes medication use and tumour characteristics at diagnosis in patients with urothelial carcinoma: a retrospective registry-based study. *Bladder Cancer* 9 (2023) 73-82.

Impactfactor: 1,1

Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Imran Omar M, Alshammari T, Areia C, Asimwe A, Beyer K, Bjartell A, Campi R, Cornford P, Falconer T, Feng Q, Gong M, Herrera R, Hughes N, Hulsen T, Kinnaird A, Lai LYH, Maresca G, Mottet N, Oja M, **Prinsen P**, Reich C, Remmers S, Roobol MJ, Sakalis V, Seager S, Smith EJ, Snijder R, Steinbeisser C, Thurin NH, Hijazy A, van Bochove K, Van den Bergh RCN, Van Hemelrijck M, Willemsse PP, Williams AE, Zounemat Kermani N, Evans-Axelsson S, Briganti A, N'Dow J; PIONEER Consortium. Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: a PIONEER analysis based on big data. *Eur Urol*. 2023 Jul 4:S0302-2838(23)02944-5. doi: 10.1016/j.eururo.2023.06.012. Online ahead of print.

Impactfactor: 23,4

Hasannejadasl H, Osong B, Bermejo I, van der Poel H, Vanneste B, van Roermund J, **Aben KK**, Zhang Z, Kiemeney L, van Oort I, Verwey R, Hochstenbach L, Bloemen E, Dekker A, Fijten RR. A comparison of machine learning models for predicting urinary incontinence in men with localized prostate cancer. *Front Oncol*. 2023 Apr 12;13:1168219. doi: 10.3389/fonc.2023.1168219. eCollection 2023.

Impactfactor: 4,7

Hasannejadasl H, Roumen C, van der Poel H, Vanneste B, van Roermund J, **Aben KK**, Kalendralis P, Osong B, Kiemeney L, van Oort I, Verwey R, Hochstenbach L, J Bloemen-van Gorp E, Dekker A, Fijten RRR. Development and external validation of multivariate prediction models for erectile dysfunction in men with localized prostate cancer. *PLoS One*. 2023 Mar 3;18(3):e0276815. doi: 10.1371/journal.pone.0276815. eCollection 2023.

Impactfactor: 3,7

Heesterman BL, **Aben KK**, de Jong IJ, Pos FJ, **van der Hel OL**. Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review. *BMC Cancer*. 2023 May 4;23(1):398. doi: 10.1186/s12885-023-10842-1.

Impactfactor: 3,8

Houben LH, Beelen M, van Loon LJ, **Beijer S**. Resistance exercise training, a simple intervention to preserve muscle mass and strength in prostate cancer patients on androgen deprivation therapy. *Int J Sport Nutr Exerc Metab*. 2023 Dec 4:1-13. doi: 10.1123/ijsnem.2023-0075. Online ahead of print. Impactfactor: 2,5

Jahreiß MC, Hoogeman M, **Aben KK**, Dirx M, Snieders R, Pos FJ, Janssen T, Dekker A, Vanneste B, Minken A, Hoekstra C, Smeenk RJ, Incrocci L, Heemsbergen WD. *Advances in radiotherapy and its impact on second primary cancer risk: a multi-center cohort study in prostate cancer patients*. *Radiother Oncol*. 2023 Mar 30:109659. doi: 10.1016/j.radonc.2023.109659. Online ahead of print. Impactfactor: 5,7

Jahreiß MC, Heemsbergen WD, Janus C, van de Pol M, Dirx M, **Dinmohamed AG**, Nout RA, Hoogeman M, Incrocci L, **Aben KK**. Impact of Advanced External Beam Radiotherapy on Second Haematological Cancer Risk in Prostate Cancer Survivors. *Clin Oncol (R Coll Radiol)*. 2023 Jan 20:S0936-6555(23)00010-9. doi: 10.1016/j.clon.2023.01.005. Online ahead of print. Impactfactor: 3,4

Jahreiß MC, Incrocci L, Dirx M, de Vries KC, **Aben KK**, Bangma C, Heemsbergen WD. Long-term overall survival after external beam radiotherapy for localised prostate cancer. *Clin Oncol (R Coll Radiol)*. 2023 Oct 4:S0936-6555(23)00341-2. doi: 10.1016/j.clon.2023.09.017. Online ahead of print. Impactfactor: 3,4

Koutros S, Kiemeny LA, Pal Choudhury P, Milne RL, Lopez de Maturana E, Ye Y, Joseph V, Florez-Vargas O, Dyrskjøt L, Figueroa J, Dutta D, Giles GG, Hildebrandt MAT, Offit K, Kogevinas M, Weiderpass E, McCullough ML, Freedman ND, Albanes D, Kooperberg C, Cortessis VK, Karagas MR, Johnson A, Schwenn MR, Baris D, Furberg H, Bajorin DF, Cussenot O, Cancel-Tassin G, Benhamou S, Kraft P, Porru S, Carta A, Bishop T, Southey MC, Matullo G, Fletcher T, Kumar R, Taylor JA, Lamy P, Prip F, Kalisz M, Weinstein SJ, Hengstler JG, Selinski S, Harland M, Teo M, Kiltie AE, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schned A, Lenz P, Riboli E, Brennan P, Tjønneland A, Otto T, Ovsiannikov D, Volkert F, Vermeulen SH, **Aben KK**, Galesloot TE, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Hohensee C, Hunt R, Patel AV, Huang WY, Thorleifsson G, Gago-Dominguez M, Amiano P, Golka K, Stern MC; UROMOL Consortium; Yan W, Liu J, Li SA, Katta S, Hutchinson A, Hicks B, Wheeler WA, Purdue MP, McGlynn KA, Kitahara CM, Haiman CA, Greene MH, Rafnar T, Chatterjee N, Chanock SJ, Wu X, Real FX, Silverman DT, Garcia-Closas M, Stefansson K, Prokunina-Olsson L, Malats N, Rothman N. *Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights*. *Eur Urol*. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.04.020. Online ahead of print. Impactfactor: 23,4

Maurits JS, Sedelaar JP, **Aben KK**, Kampman E; ReLife study group; Kiemeny LA, Vrieling A. Cohort profile - the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands. *BMJ Open*. 2023 Mar 27;13(3):e066909. doi: 10.1136/bmjopen-2022-066909. Impactfactor: 2,9

Nuijens ST, van Hoogstraten LM, Meijer RP, Kiemeny LA, **Aben KK**, Witjes JA. Minimum Volume Standards: An Incentive To Perform More Radical Cystectomies? *Eur Urol Open Sci*. 2023 Mar 31;51:47-54. doi: 10.1016/j.euros.2023.02.015. eCollection 2023 May. Impactfactor: 2,5

Overkamp M, **Houben LH**, van der Meer S, van Roermund JG, Bos R, Kokshoorn AP, Larsen MS, van Loon LJ, Beelen M, **Beijer S**. Onset of androgen deprivation therapy leads to rapid deterioration of body composition, physical performance, cardiometabolic health and quality-of-life in prostate cancer patients. *Scand J Urol*. 2023 Jan 26:1-7. doi: 10.1080/21681805.2023.2168050. Online ahead of print. Impactfactor: 1,5

Overkamp M, **Houben LH**, Aussieker T, van Kranenburg JM, Pinckaers PJ, Mikkelsen UR, Beelen M, **Beijer S**, van Loon LJ, Snijders T. Resistance exercise counteracts the impact of androgen deprivation therapy on muscle characteristics in cancer patients. *J Clin Endocrinol Metab*. 2023 May 10:dgad245. doi: 10.1210/clinem/dgad245. Online ahead of print. Impactfactor: 5,8

Rammant E, Fox L, Beyer K, Aaronson NK, Chaloner R, De Padova S, Liedberg F, Wintner LM, Decaestecker K, Fonteyne V, Perdek N, Wylie H, Catto JWF, **Ripping TM**, Holzner B, van Leeuwen M, van Hemelrijck M; EORTC Quality of Life Group. The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review. *Qual Life Res.* 2023 Jan 17. doi: 10.1007/s11136-022-03335-4. Online ahead of print. Impactfactor: 3,5

Richters A, Yildirim H, Booth CM, Vera Badillo FE, Kiemeney LA, **Aben KK**. Changes to primary end points in randomized clinical trials on immune checkpoint inhibitors in urothelial, renal cell, and lung cancers: a systematic review. *JAMA Oncol.* 2023 Jun 8:e231374. doi: 10.1001/jamaoncol.2023.1374. Online ahead of print. Impactfactor: 28,4

Richters A, van Ginkel N, Meijer RP, Wondergem M, Schoots I, Vis AN, Kiemeney LA, van Rhijn BW, Witjes JA, **Aben KK**, Mertens LS. Staging FDG-PET/CT for muscle-invasive bladder cancer: a nationwide population-based study. *BJU Int.* 2023 May 28. doi: 10.1111/bju.16091. Online ahead of print. Impactfactor: 4,5

Roy P, van Peer SE, Dandis R, Duncan C, de Aguirre-Neto JC, Verschuur A, de Camargo B, **Karim-Kos HE**, Boschetti L, Spreafico F, Ramirez-Villar GL, Graf N, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM. Impact of the COVID-19 pandemic on paediatric renal tumour presentation and management: a SIOP renal tumour study group study. *Cancer Med.* 2023 Jul 26. doi: 10.1002/cam4.6358. Online ahead of print. Impactfactor: 4

Sieswerda M, Xie S, van Rossum R, Bermejo I, **Geleijnse G, Aben KK, van Erning FN, Lemmens VL**, Dekker A, **Verbeek X**. Identifying Confounders Using Bayesian Networks and Estimating Treatment Effect in Prostate Cancer With Observational Data. *JCO Clin Cancer Inform.* 2023 Jan;7:e2200080. doi: 10.1200/CCI.22.00080. Impactfactor: 4,2

Tillier CN, Boekhout AH, Veerman H, Wollersheim BM, Groen P, van der Poel HG, **van de Poll-Franse LV**. Patient-reported outcome measures compared to clinician reported outcomes regarding incontinence and erectile dysfunction in localized prostate carcinoma after robot assisted radical prostatectomy: impact on management. *Urol Oncol.* 2023 Sep 8:S1078-1439(23)00262-4. doi: 10.1016/j.urolonc.2023.08.001. Online ahead of print. Impactfactor: 2,7

van Hoogstraten LM, Vrieling A, van der Heijden AG, Kogevinas M, **Richters A**, Kiemeney LA. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. *Nat Rev Clin Oncol.* 2023 Mar 13. doi: 10.1038/s41571-023-00744-3. Online ahead of print. Impactfactor: 78,8

van Hoogstraten LM, Man CC, Witjes JA, Meijer RP, Mulder SF, Smilde TJ, **Ripping TM**, Kiemeney LA, **Aben KK**; BlaZIB Study Group. Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *World J Urol.* 2023 May 31:1-9. doi: 10.1007/s00345-023-04443-7. Online ahead of print. Impactfactor: 3,4

van Puffelen JH, Novakovic B, van Emst L, Kooper D, Zuiverloon TC, Oldenhof UT, Witjes JA, Galesloot TE, Vrieling A, **Aben KK**, Kiemeney LA, Oosterwijk E, Netea MG, Boormans JL, van der Heijden AG, Joosten LA, Vermeulen SH. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections. *J Immunother Cancer.* 2023 Jan;11(1):e005518. doi: 10.1136/jitc-2022-005518. Impactfactor: 10,9

van Zutphen M, Hof JP, **Aben KK**, Kampman E, Witjes JA, Kiemeney LA, Vrieling A. Adherence to lifestyle recommendations after non-muscle invasive bladder cancer diagnosis and risk of recurrence. *Am J Clin Nutr.* 2023 Feb 11:S0002-9165(23)04155-2. doi: 10.1016/j.ajcnut.2022.12.022. Online ahead of print. Impactfactor: 7,1

van Zutphen M, Beeren I, **Aben KK**, van der Heijden AG, Witjes JA, Kiemeney LA, Vrieling A. Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer. *Cancer Med.* 2023 Oct 6. doi: 10.1002/cam4.6620. Online ahead of print. Impactfactor: 4,0

van Zutphen M, Kiemeney LA, Oldenhof UT, Maurits JS, Witjes JA, Joosten LA, Netea MG, **Aben KK**, Vrieling A, Vermeulen SH. No association between BCG instillations and COVID-19 incidence in a Dutch non-muscle invasive bladder cancer cohort. *Bladder Cancer* 9 (2023) 355-363. Impactfactor: 1,1

Vidra N, Beeren I, van Zutphen M, **Aben KK**, Kampman E, Witjes JA, van der Heijden AG, Kiemeney LA, Vrieling A. Longitudinal associations of adherence to lifestyle recommendations and health-related quality of life in patients with non-muscle invasive bladder cancer. *Int J Cancer.* 2023 Jan 3. doi: 10.1002/ijc.34418. Online ahead of print. Impactfactor: 6,4

Yildirim H, Widdershoven CV, Aarts MJ, Bex A, Bloemendal HJ, Bochove-Overgaauw DM, Hamberg P, Herbschleb KH, van der Hulle T, Lagerveld BW, van Oijen MG, Oosting SF, van Thienen JV, van der Veldt AA, Westgeest HM, Zeijdner EE, **Aben KK**, **van den Hurk CJ**, Zondervan PJ, Bins AD. The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs. *BMC Cancer.* 2023 Jul 11;23(1):648. doi: 10.1186/s12885-023-11094-9. Impactfactor: 3,8

12.2 Overige publicaties

van Ginkel N, Vis AN, Boormans JL, van der Poel HG, van der Schoot DK, **Aben KK**, Hermans TJ, Meijer D, Voortman J, Arends TJ, Ausems PJ, Baselmans D, Berger CP, Berrens AC, Bickerstaffe H, Bos SD, Braam M, Buddingh KT, Claus S, Dekker K, van Doeveren T, Einerhand SM, Fossion LM, Hinseveld FJ, van Gennep EJ, Grondhuis Palacios LA, Hobijn MM, van Huystee SH, Jaspers-Valentijn M, Klaver OS, Koldewij EL, Korsten L, Lenting A, Lentjes KJ, Luiting HB, van der Meer S, Mertens L, Nieuwenhuijzen JA, Noordzij MA, Nooter RI, Notenboom M, Oomen RJ, van Roermund JG, de Rooij J, Roshani H, Schrier BP, van der Slot MA, Somford DM, Stelwagen PJ, Stroux AM, van der West A, Wijsman BP, Windt WA, van Zanten P, van Beek SC. Middellangetermijnoverleving na open versus robotgeassisteerde radical cystectomie in Nederland: resultaten van de SNAPSHOT cystectomie. *Tijdschr Urol* 2023 Nov 164-175.

van Ginkel N, Meijer D, Boormans JL, Mertens LS, van Beek SC, Vis AN; The Dutch Cystectomy Snapshot Research Group (**Aben KK**). Predictors of major complications and the association with oncological outcomes after radical cystectomy for bladder cancer: a nationwide registry study. *Med. Res. Archives* 2023 Jun;11(6). doi: <https://doi.org/10.18103/mra.v11i6.3978>.

Yildirim H, **Schuurman MS**, Widdershoven CV, Lagerveld BW, van den Brink L, Ruiters AE, Beerlage HP, van Moorselaar RJ, Graafland NM, Bex A, **Aben KK**, Zondervan PJ. Variation in the management of cT1 renal cancer by surgical hospital volume: a nationwide study. *BJUI Compas* 2023 Mar 1. doi.org/10.1002/bco2.229.

12.3 Proefschriften en promoties

van Hoogstraten LMC. Bladder cancer care in the Netherlands: guidelines and practice: are they in harmony? Nijmegen: Radboudumc; 19 december 2023. Promotores: LA Kiemeney, J Witjes. Copromotores: **KK Aben**, RP Meijer.

B1 Impactfactoren tijdschriften

Tabel 1 Overzicht tijdschriften met impactfactor

<i>Naam tijdschrift:</i>	<i>Impactfactor:</i>	<i>Aantal publicaties:</i>
Acta Obstetricia et Gynecologica Scandinavica	4,3	1
Acta Oncologica	3,1	5
Aging & Mental Health	3,4	1
American Journal of Clinical Nutrition	7,1	1
American Journal of Hematology	12,8	1
American Journal of Hospice and Palliative Medicine	1,9	1
Annals of Behavioral Medicine	3,8	1
Annals of Oncology	50,5	1
Annals of Surgical oncology	3,7	16
BJCP British Journal of Clinical Psychology	3,1	1
BJS Open	3,2	1
BJS British Journal of Surgery	9,6	1
BJU International	4,5	1
Bladder Cancer	1,1	2
Blood Advances	7,6	2
Blood Cancer Journal	12,8	3
BMC Cancer	3,8	6
BMC Palliative Care	3,1	2
BMJ Open	2,9	2
BMJ Open Quality	1,4	1
BMJ Supportive and Palliative Care	2,7	1
Breast Cancer Research	7,4	1
Breast Cancer Research and Treatment	3,8	7
Canadian Journal of Surgery	2,5	1
Cancer	6,2	3
Cancer Cell	50,3	1
Cancer Epidemiology	2,6	3
Cancer Medicine	4,0	6
Cancer Research	11,2	1
Cancers (Basel)	5,2	7
Clinical & Experimental Metastasis	4,0	2
Clinical Nutrition ESPEN	3,0	1
Clinical Oncology	3,4	2
Critical Reviews in Oncology/Hematology	6,2	1
Diseases of the esophagus	2,6	1
EClinical Medicine	15,1	5
EJC European Journal of Cancer	8,4	8
EJSO European Journal of Surgical Oncology	3,8	5
Endoscopy	9,3	1
ESMO Open	7,3	2
European Archives of Oto-Rhino-Laryngology	2,6	1
European Geriatric Medicine	3,8	2
European Journal of Haematology	3,1	1
European Journal of Neurology	5,1	1
European Journal of Oncology Nursing	2,8	1
European Urology	23,4	2
European Urology Oncology	8,2	1
European Urology Open Science	2,5	1
Frontiers in Oncology	4,7	9
Gastric Cancer	7,4	1
Gastroenterology	29,4	1
Gynecologic Oncology	4,7	2
Haematologica	10,1	3

Hemasphere	9,1	3
HPB	2,9	2
IJC International Journal of Cancer	6,4	6
Indian Journal of Surgical Oncology	0,5	2
International Journal of Colorectal Disease	2,8	1
International Journal of Epidemiology	7,7	1
International Journal of Gynecological Cancer	4,8	1
International Journal of Radiation Oncology Biology Physics	7,0	3
International Journal of Sport Nutrition and Exercise Metab.	2,5	1
iScience	5,8	2
JAAD Journal of the American Academy of Dermatology	13,8	2
JAMA Network Open	13,8	2
JAMA Oncology	28,4	1
JCO Clinical Cancer Informatics	4,2	2
JCO Precision Oncology	4,6	1
JMIR Research Protocols	1,7	1
JMRI Journal of Magnetic Resonance Imaging	4,4	1
JNCI Cancer Spectrum	4,4	1
JNCI Journal of the National Cancer Institute	10,3	5
Journal for Immunotherapy of Cancer	10,9	1
Journal of Advanced Nursing	3,8	1
Journal of Cancer Research and Clinical Oncology	3,6	1
Journal of Cancer Survivorship	3,7	10
Journal of Clinical Endocrinology & Metabolism	5,8	1
Journal of Clinical Epidemiology	7,2	1
Journal of Dermatology	3,1	1
Journal of Gastroenterology	6,3	1
Journal of Medical Internet Research	7,4	1
Journal of Neuro-Oncology	3,9	1
Journal of Occupational Rehabilitation	3,3	1
Journal of patient-reported outcomes	2,7	2
Journal of the European Academy of Dermatology and Ven.	9,2	2
Learning Health Systems	3,1	1
Lung Cancer	5,3	2
Maturitas	4,9	1
Nature Reviews Clinical Oncology	78,8	1
Nature Medicine	82,9	1
NPJ science of food	6,4	2
Nursing Ethics	4,2	1
Oncology Letters	2,9	1
Open Heart	2,7	1
Oral Oncology	4,8	1
Palliative Medicine	4,4	1
PharmacoEconomics	4,4	1
Photochemical & Photobiological Sciences	3,1	1
Plos One	3,7	2
Preventive Medicine	5,1	1
Primary Health Care Research & Development	1,6	1
Psychology & Health	3,3	1
Psycho-Oncology	3,6	2
Quality of Life Research	3,5	3
Radiology	19,7	1
Radiotherapy & Oncology	5,7	3
Scandinavian Journal of Urology	1,5	1
Scientific Reports	4,6	1
Seminars in Oncology Nursing	2,2	1
Supportive Care in Cancer	3,1	18
Surgical Endoscopy	3,1	1
The Breast	3,9	3
The Lancet Oncology	51,1	3
The Lancet Regional Health Europe	20,9	1

The Oncologist	5,8	1
Therapeutic Advances in Medical Oncology	4,9	1
Thrombosis Research	7,5	1
Thyroid Research	2,2	1
Translational Lung Cancer Research	4,0	1
Transplantation	6,2	1
Urologic Oncology: seminars and original investigation	2,7	1
Value in Health	4,5	1
Virchows Archiv	3,5	1
World Journal of Surgical Oncology	3,2	2
World Journal of Urology	3,4	1
ZEFQ Zeitschrift für evidenz, fortbildung und qualität im Gesundheitswesen	1,1	1

Tabel 2 Overzicht tijdschriften zonder impactfactor

<i>Naam tijdschrift:</i>	<i>Aantal publicaties:</i>
Archives of Women Health and Care	1
BJUI Compass	1
Breast Disease	2
Die Onkologie	1
International Environmental Research and Public Health	1
JTO Clinical and Research Reports	1
Measurement and evaluations in cancer care	2
Medical Research Archives	1
NtvG Nederlands Tijdschrift voor Geneeskunde	3
Palliative Care and Social Practice	1
Research Square	1
Studies in Health Technology and Informatics	1
Tijdschrift voor Urologie	1

Integraal Kankercentrum
Nederland
info@iknl.nl
www.iknl.nl

